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ABSTRACT 
To date, the complex nature of the host’s response to the human immunodeficiency virus 
still intensely studied.  Amongst the contributing factors to the host responses are chemokines. 
Attention to the role of homeostatic chemokines in HIV-1 infection has been concentrated on 
changes in their constitutive expression.  There is evidence that demonstrates the expession 
levels of CXCL9 and CXCL13 are increased during infection.  CXCL13 is a homeostatic, 
constitutively expressed chemokine responsible for the migration of lymphocytes into the 
germinal centers of lymphoid tissues.  I examined the levels and locations of CXCL13, amongst 
other homeostatic chemokines, and local cell populations by detailed in situ methods in macaque 
lymphoid and intestinal tissues.  My results indicate that there were distinct localization patterns 
of CXCL13 mRNA compared to protein in germinal centers.  These patterns shifted during the 
course of SIV infection, with increased mRNA expression within and around follicles during 
AIDS compared to uninfected or acutely infected animals.  Unexpectedly, CXCL13 expression 
was also found in abundance in Paneth cells in crypts throughout the small intestine.  In the 
gastrointestinal tract, Paneth cells produce antimicrobial peptides as an innate immune 
mechanism to protect the epithelium from pathogenic infection.  Therefore, I expanded my 
analyses to include Paneth cells, and chemokines and antimicrobial peptides not previously 
demonstrated to be expressed by Paneth cells in intestinal tissues.   I examined the expression 
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 v 
patterns of multiple chemokines including CCL25, as well as antimicrobial peptides including α-
defensins 6, β-defensin 2, rhesus θ-defensin 1, and Reg3γ. Additionally, I evaluated other Paneth 
cell-associated factors in situ in cynomolgous macaque intestinal tissues.  Results showed that no 
other chemokines were expressed by Paneth cells, making CXCL13 unique among the group.  
DEFA1, BDEF2, RTD-1, and Reg3γ expression was also clearly in Paneth cells and localized to 
the same cellular compartment as CXCL13 and DEFA6.  These peptides have not been shown 
previously to be expressed by Paneth cells.  I also found that during SIV infection there are 
differences in the expression levels of several antimicrobial peptides.  These findings are of 
public health importance because they expand our understanding of mucosal immunology, innate 
antimicrobial defenses, homeostatic chemokine function, and host protective mechanisms against 
microbial translocation.   
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1.0  INTRODUCTION 
Chemokines are critical contributors to immune function and development.  They are 
small, secreted proteins that mediate the trafficking of cells during normal and inflammatory 
conditions.  The functional activities of chemokines are diverse.  They play critical roles in the 
migration of immune cells as part of the homeostatic balance of the immune system and in 
drawing the appropriate responding cell populations to sites of inflammation.   Chemokines are 
also widely known to possess apoptotic, anti-apoptotic and/or chemorepulsive properties as well 
as antimicrobial activity against bacterial and viral pathogens.  Manipulating the 
chemokine/chemokine receptor network could be a reasonable target for prevention or treatment 
of pathogenic infections.  This very idea has been illustrated and highly instrumental in treating 
HIV-1 infection using a strategy that is not directly antiretroviral.  To gain entry into a 
macrophage or T cell, HIV-1 requires the usage of two receptors: CD4 and either CCR5 or 
CXCR4.  CCR5 is the primary coreceptor used during HIV transmission and infection.  
Maraviroc, a CCR5 chemokine receptor antagonist that prevents this viral entry, is the first of its 
kind to be approved by the Federal Drug Administration (FDA) for treatment of R5-tropic viral 
infection in humans.   This exemplifies the value in studying chemokine and chemokine receptor 
expression and function during infections, which is the focus of this dissertation.  
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1.1  CHEMOKINES 
Chemokines are small proteins that signal through seven transmembrane domain G 
protein coupled receptors (GPCRs).1  They are chemotactic cytokines that direct the trafficking 
of leukocytes through the blood, tissues and lymphatics.  Chemokines are classified based on 
their structure and the configuration of the cysteine residues at their N-termini.  As such, there 
are approximately 50 C, CC, CXC, and CX3C chemokines.  Although they are commonly 
known for their migratory function, chemokines have additional functions.  A few of these 
functions include protection from apoptosis, angiogenesis, anti-angiogenesis, T cell polarization, 
and DC licensing and each of these mechanisms is suspected to be modified during SIV 
infection.2   
Chemokines can be grouped as either inflammatory or homeostatic.  Inflammatory 
chemokines have been described as such because of their ability to draw leukocytes to sites of 
inflammation.  These chemokines are produced under pathological conditions by infiltrating or 
endogenous cells to the affected tissue.  Alternatively, there are also chemokines involved in 
normal housekeeping functions, including the maturation of leukocytes in the bone marrow and 
the regeneration of circulating leukocytes.3  These chemokines are homeostatic chemokines.  
They are constitutively expressed and they maintain the normal trafficking of immune cells 
throughout all tissues in the body.4  Amongst the group of homeostatic chemokines are CCL19, 
CCL21, CCL25, CCL28, CXCL12, and CXCL13, which direct constitutive trafficking to lymph 
nodes (LNs), gut-associated lymphoid tissues (GALT), and germinal centers, respectively.   
 Chemokines bind to a superfamily of seven-transmembrane domain GPCRs.   CXC-
chemokines bind to their corresponding CXC-receptors, whereas CC-chemokines bind to CC-
receptors.   There are approximately 20 chemokine receptors that have been identified.1  When a 
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chemokine binds to its cell receptor signal transduction occurs and cells migrate up a chemokine 
gradient.  The chemokine receptor then undergoes internalization ensuing in a cell refractory 
period.1   
 A common function of chemokines and chemokine receptors is control of migration of 
cells to sites of infection and inflammation.  Tissue damage and inflammatory diseases result 
when there is excessive recruitment of cells by chemokines and their receptors.  Examples of this 
have been demonstrated in individuals with chronic obstruction pulmonary disease (COPD) and 
multiple sclerosis (MS).5,6  AIDS is another disease where chronic inflammation is mediated by 
chemokines and their receptors.7 
1.2 HIV/SIV/AIDS 
HIV/AIDS is one of the largest pandemics to impinge on man, affecting over 60 million 
people worldwide.8  This global public health issue recently reached its 30th anniversary and 
despite tremendous advancements and effort by the scientific community in understanding the 
virus and consequences of infection, disease eradication and prevention, the virus maintains the 
upper hand in this battle.  According to the 2012 UNAIDS report, globally, there are 34.2 million 
people living with HIV-1.  In 2011, there were 2.5 million people newly infected with HIV-1.  
This amounts to over 7,000 new cases of HIV-1 infection per day.  In 2011, 1.7 million people 
suffered AIDS-related deaths, a reduction from the 2.3 million deaths reported in 2005 
(UNAIDS), but nevertheless the epidemic continues.   
Acquired immunodeficiency syndrome (AIDS) was first described in 1981.9  It was two 
years before human immunodeficiency virus (HIV-1), was isolated as the etiological agent of 
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this disease.10  Originally termed lymphadenopathy-associated virus (LAV)10, human T 
lymphotropic virus (HTLV)-III,11 or AIDS-associated retrovirus (ARV)12 individuals infected 
with HIV-1 suffer from suppression of their immune system that renders the body vulnerable to 
opportunistic infections and multiple forms of cancer.13  AIDS is a slow progressing disease that 
is spread through sexual contact, through contaminated blood and blood products, and by 
mother-to-child transmission.13   
HIV-1 is a lentivirus and a member of the Retroviridae family of viruses.  It primarily 
infects CD4+ T cells and macrophages, gaining entry to a cell via fusion to a target cell by 
binding of the viral envelope glycoprotein gp120 to the CD4 target cell surface receptor.  Though 
the process of binding to CD4 is essential for vial entry, the virus must also bind to a co-receptor 
to gain full entry to a target cell.  Chemokine receptors CXCR4 and CCR5 are the required co-
receptors needed by the virus.  gp120 on the viral envelope binds to CD4 on the target cell and 
leads to a conformational change that exposes the structural elements on the V3 loop of gp120.   
The V3 loop and the co-receptor CCR5 or CXCR4 on the cell surface interact and result in a 
second conformational change allowing viral glycoprotein, gp41, to be revealed.  gp41 then 
binds with the CD4+ cell membrane, leading to fusion of the membranes, and ultimately 
allowing the viral core access into the CD4+ cell cytoplasm.14-16  Expression levels of CXCR4 
and CCR5 have been evaluated in HIV-1 CD4+ cells and it has been shown that advanced 
disease is associated with lower expression of CXCR4 and higher levels of CCR5 on those 
cells.17   2003).    
Cross-species transmission of SIV is the major source of pathogenic infections in 
humans.18 HIV-1 and HIV-2 are two types of human AIDS viruses.  HIV-1 is responsible for the 
global AIDS pandemic, and HIV-2 causes AIDS in regions of West Africa.  These two types of 
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human AIDS viruses are distinguished from one another based on their evolutionary relationship 
with other primate lentiviruses.  HIV-1 originated from the simian immunodeficiency virus 
(SIV) found in African chimpanzees and gorillas.  More specifically, HIV-1 was confirmed by 
sequence and phylogenetic analysis to be a result of cross-species transmission of SIVs from 
chimpanzees (SIVcpz).18-20  HIV-1 consists of three groups: M, N, and O.  Group M makes up 
the largest group with 11 clades denoted subtypes A through K.  The majority of HIV-1 group M 
viruses arose from one cross-species event.  HIV-1 and SIVcpz were first linked as originating 
from the same viral lineage based on the presence of the vpu gene in their genomic structure.19,21  
The roots of HIV-1 have been traced to the western region of Africa that includes Gabon, 
Equatorial Guinea, Cameroon, and the Republic of Congo.  In this region HIV-1 subtypes M, N, 
and O coexist within human populations where Pan troglodytes troglodytes chimpanzees 
infected with the closely related SIVcpz also reside.19,20,22  HIV-2 consists of six phylogenetic 
subtypes termed A through F.18   HIV-2 arose from at least eight cross-species events by SIV 
from sooty mangabeys (SIVsm).  Both viruses code for the accessory protein VPX encoded in 
their genomic structure and are within the same phylogenetic lineage.23,24    
There are multiple and complex events that define the course of HIV-1 and progression to 
AIDS.  These include the acute phase, partial immune restoration, clinical latency, and AIDS.  
The acute phase of infection is characterized by HIV-1 infection of a target cell, which quickly 
spreads amongst the CD4+ T cell population, and leads to the onset of generalized chronic 
immune activation.   During this time polyclonal B-cell activation occurs, along with increases in 
the activated phenotypes of T-cells, and increased production of pro-inflammatory cytokines and 
chemokines.25,26  The blood contains high levels of viremia.  Viral integration into the host cell 
DNA occurs and allows the virus to evade the host immune system.  The virus then lies dormant 
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for an extended period of time without being expressed.  Two to four weeks post-infection CD8+ 
T cells mount an immune response that lowers viral replication and restores CD4+ T cell levels.  
Subsequently, the virus undergoes a latency phase, during which the host remains symptom-free 
for several years despite ongoing viral replication.  AIDS occurs when the host’s overly 
stimulated immune system is no longer capable of combating viral replication and becomes 
susceptible to opportunistic infections.  An individual is clinically defined with AIDS once their 
CD4+ T cell count is below 200 CD4+ T cells per cubic millimeters of blood and they are 
diagnosed with one or more opportunistic infections.27   
Despite isolation of HIV in 1983, it was approximately two more years until the first 
form of treatment was developed.  Azidothymidine (AZT) was the first commercially available 
anti HIV-1 drug approved for the treatment of patients with advanced disease.  AZT, a 
dideoxynucleoside reverse trascriptase inhibitor (RTI)28 acts directly to block reverse 
transcription, the copying of the viral RNA genome to DNA.   Successive anti HIV-1 
therapeutics included non-nucleoside RT inhibitors (NRTI), protease inhibitors (PI), fusion/entry 
inhibitors, integrase inhibitors, maturation inhibitors, and highly active antiretroviral treatment 
(HAART), which is the combination of two or more antiretroviral drugs.  The use of HAART 
delays disease progression and slows viral replication, therefore, reducing viral loads.29   
Compared to antiretroviral therapy, the development of an HIV-1 vaccine has proven 
much more difficult for HIV/AIDS researchers.  Vaccine studies have concentrated on the 
development of two types of immune responses for ideal prophylactic vaccine candidates: 1) a 
humoral or B cell response that can generate neutralizing antibodies to inhibit viral entry; or 2) a 
T-cell based vaccine that stimulates a specific T-cell responses to curb viral propagation.   The 
very nature of the virus has presented many obstacles in vaccine development.    
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AIDS research and vaccine trials rely on the use of animal models that emulate HIV-1 
infection in humans.  Mimicking HIV-1 infection routes in humans has been difficult without a 
model system that completely recapitulates the process that occurs in humans.  HIV-1 developed 
from cross-species transmission of SIVcpz from chimpanzees and gorilla.  However, the use of 
chimpanzees as an animal model for human infection has not proven to be the best model given 
these animals do not show disease development in captivity.30,31   
In contrast, there are other non-human primates that provide useful models to study 
HIV/SIV pathogenesis.  These NHPs harbor similar cell types that are susceptible to viral 
infection, suffer from the severe depletion of CD4+ 
32
T cells in the GALT and are vulnerable to 
opportunistic infections.   In addition, they exhibit virological and immunological characteristics 
of acute infection that are very similar to those observed in humans.33  Asian macaques are non-
natural hosts of SIV and develop disease similarly to HIV-1 in humans although at a rapid rate.  
Disease progression to AIDS occurs within 1-2 years compared to 8-10 years in humans.  The 
three most-commonly used macaque species for HIV-1 animal studies are the rhesus macaque 
(Macaca mulatta), the pig-tailed macaque (Macaca nemestrina) and the cynomolgus macaque 
(Macaca fascicularis).  These macaques differ in their usage in HIV studies due to the lack of 
availability of some Indian and Chinese species and in the severity of the pathogenesis of the 
infected viral strain.    
HIV-2 developed from cross-species transmission of SIVsmm from sooty mangabeys.23  
Sooty mangabeys and African green monkeys are natural SIV hosts that are used as a model of 
non-pathogenic SIV.  These animals do not develop disease and serve for comparison between 
non-pathogenic and pathogenic SIV infection.  In these natural hosts they exhibit induction of 
viral replication, severe depletion of mucosal CD4+ T cells and the activation of innate and 
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adaptive immunity.34  In contrast from non-natural SIV hosts, the viruses circulated among these 
animals do not cause chronic immune activation, depletion of mucosal or peripheral CD4+ 
32
T 
cells, or destruction of lymph node architecture. ,34  
1.3 CHEMOKINE RESPONSES TO HIV/SIV INFECTION 
In the late 90’s investigators deemed the chemokine and chemokine receptor network as 
essential to understanding AIDS.35  Today, the roles chemokines play in SIV pathogenesis are 
still extensively studied.  The chemokines CCL3, CCL4, and CCL5, also known as MIP-1α, 
MIP-1β, and RANTES respectively, are considered potential suppressive factors for HIV-1 and 
SIV.36  Cocchi et al., first provided evidence that CD8+ T cell production of these chemokines 
suppressed HIV-1 activity.  Subsequently, it was determined that the receptors for these 
chemokines served as viral entry co-receptors for HIV-1, HIV-2 and SIV.37-40  Initial studies 
showed that the cellular determinants of viral entry were not only the presence of CD4, but also a 
fusion cofactor on the CD4+ target cell.   CXCR4, also known as fusin, and CCR5, originally 
termed CC CKR5 (CC chemokine receptor 5), were the primary cofactors found to permit HIV-1 
infection.37-39  HIV-1 isolates that preferentially infect CD4+ T cell with CXCR4 on their surface 
are termed T-tropic or X4 viruses.  For viral entry to occur, HIV-1 adheres to a target cell by 
gp120 interacting with both CD4 and CXCR4.  This induces conformational changes in the 
gp120/gp41 complex that allow membrane fusion by gp41.   
Unlike the specific expression of CXCR4 on T cells, CCR5 expression is found mostly 
on macrophages with some expression by CD4+ T cells.  HIV-1 isolates that infect CCR5+ cells 
are termed M-tropic or R5 viruses.38  In cases of R5 viral infection, HIV-1 gp120 binding to 
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CCR5 is CD4-dependent.  Antibody inhibition of CCR5 provides reduction of binding of HIV 
gp120 to CCR5 by 87%.41  There are individuals who possess a 32 nucleotide deletion (∆32) 
homozygous genotype that results in the absence of surface-expressed CCR5, rendering them 
resistant to HIV-1 infection.39,42-44  The ∆32 mutation does not result in any evident effects 
detrimental to the host.  Reduction in cell surface expression of CCR5 in individuals that contain 
the ∆32 mutation  is associated with a slower rate of disease progression after HIV-1 
infection.45,46  In 1998, Moriuchi et al., provided evidence that showed upregulation of CXCR4 
expression on macrophages allows infection by X4 viruses.47  Over the course of infection, 
coreceptor usage transfers from predominantly CCR5 over to CXCR4 usage.  Approximately, 
50% of individuals infected with HIV-1 display a switch to CXCR4 preference upon disease 
progression and the decline in CD4+ T cell levels.35,46,48  This coreceptor shift is caused by 
mutations that occur in the viral life cycle and allow the virus to infect a larger population of 
cells. 
The use of anti-retrovirals, such as AZT or HAART, in combating HIV infection can be 
efficacious at inhibiting disease progression.  However, adverse side effects of the drugs can 
result in poor adherence by HIV-1 infected patients.  The development of novel antiretrovirals 
has been driven largely by the emergence of drug resistant viral strains but also by efforts to 
reduce toxicity.   Given that the ∆32 CCR5 mutation is not harmful to the immune system, CCR5 
is a prime candidate for drug and vaccine approaches.  Maraviroc was the first early entry 
inhibitor approved by the FDA.  It acts by preventing binding of HIV-1 gp120 to CCR5 and 
inhibiting the conformational changes necessary for viral entry into target cells.49        
There have been efforts to examine modifications to host chemokine gene expression 
after SIV infection.  A study has identified changes in CXCL9 expression during SIV infection.7  
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They showed upregulation of CXCL9 in rhesus macaque lymphoid tissues during SIV infection 
and developed a basic model that proposed a possible mechanism in which IFN-γ-inducible 
chemokines are upregulated, causing a positive-feedback loop that could serve as a source 
chronic inflammation during SIV infection.7  They found that CXCL13 was among the genes 
that were upregulated in spleen tissues during SIV infection.  Another interesting aspect about 
this chemokine is that it has also been described as an agonist for the CXCR3 chemokine 
receptor.50  It has been  described how during infection there is an induction of IFN-γ that results 
in an increase in CXCR3 ligand secretion which then causes an increase in recruitment of 
CXCR3+ T-lymphocytes.7  This could signify that CXCL13 could contribute to the positive-
feedback loops driven by IFN-γ. 
1.4 CXCL13 
CXCL13 is a member of the homeostatic functional group of chemokines and signals 
through its receptor CXCR5.   CXCL13 was originally termed B-lymphocyte chemoattractant 
(BLC) and was found in the germinal centers (GC) of lymphoid follicles in the lymph nodes, 
spleen and Peyer’s patches.51,52  Subsequently, it was also detected on high endothelial venules 
(HEV) of the secondary lymphoid organs.53  CXCL13 is secreted by stromal cells located in the 
follicles of lymphoid tissues, although other cells might also produce it.  CXCL13 drives 
migration of B cells, follicular helper T cells (Tfh), and a subset of dendritic cells (DCs) to the 
follicles of lymphoid organ.51   
CXCL13 also has been implicated in the formation of ectopic lymphoid tissue in chronic 
inflammation.  Examples of this can be seen in cases of multiple sclerosis (MS) and rheumatoid 
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arthritis (RA).54,55   In MS, CXCL13 is expressed in active MS lesions.54  MS patients show 
induced expression of this chemokine in cerebral spinal fluid (CSF) and these levels correlate 
with the number of B cells present in the CSF of patients with clinically isolated syndrome (CIS) 
and relapsing-remitting MS (RRMS).54,56  Of late, CXCL13 is suggested to be a prognostic 
marker for MS, and increased concentrations of CXCL13 in CSF are positively correlated with 
increased MS disease activity.57 
CXCL13 in CSF also can be found in other infections and inflammatory conditions of the 
central nervous system (CNS).58,59  It has been observed at high levels in Lyme 
neuroborreliosis60 (NB) and is a key factor in Lyme disease of skeletal muscle in NHPs.61  In 
humans, elevated levels of CXCL13 are found in the CSF of European patients with Lyme NB.58  
Multiple studies have evaluated and confirmed the induction of CXCL13 during Lyme disease 
and have proposed CXCL13 as both a diagnostic and therapy-response marker in Lyme NB.62-64    
Helicobacter pylori is a Gram(-) bacterium that resides in the upper GI tract and has been 
linked to cases of gastritis and gastric ulcers.  Chronic inflammation is one of the 
pathophysiologic characteristics of this disease and includes the formation of mucosa-associated 
lymphoid tissue (MALT).65,66  CXCL13 has been implicated as the driving force in the 
development of lymphoid aggregates and gastric lymphomas in a normally MALT-deficient 
region of the GI tract.67  In a similar fashion, in 2002, Carlsen et al. examined a possible role for 
CXCL13 and CXCR5 in normal gut associated lymphoid tissues (GALT) by comparing its 
expression in normal and diseased colonic tissues.68  These authors described the secretion of 
CXCL13 by aberrant lymphoid aggregates in the colonic tissue of patients with ulcerative colitis 
.68   
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Although this homeostatic chemokine is predominantly involved in chemotaxis of 
lymphocytes, it also has antimicrobial properties.  In 2002, Yang et al. found that CXCL13 was 
among a group of chemokines, including CCL20, with the ability to kill microbes.69  In an 
antimicrobial assay, CXCL13 showed antimicrobial activity against Escherichia coli and 
Staphylococcus aureus.  In this manner, CXCL13 is acting similarly to defensins.70  Defensins 
are cationic antimicrobial peptides (AMPs) that are secreted by polymorphonuclear leukocytes 
and other epithelial cells, such as Paneth cells, in response to bacterial, fungal and viral 
pathogens.71  The functions of defensins also seem to overlap the functions chemokines as at 
least some of them are both chemotactic for CD4, CD8 and DCs and they stimulate 
degranulation of leukocytes.72  The structures of chemokines and defensins are also similar in 
that they both contain highly conserved cysteine residues.  Defensins are produced and secreted 
by many cell types.  One specialized cell that is unique to the small intestine and is a major 
source for intestinal defensins is the Paneth cell.   
1.5 CXCL13 & HIV 
 
Few studies have evaluated changes in CXCL13 expression and function during HIV-1 or 
SIV infection.  In 2005, Widney et al. evaluated serum samples from HIV-1+ subjects who were 
healthy or in advanced disease and compared them to healthy uninfected control subjects and 
they determined that the mean serum CXCL13 levels are three-fold higher in those individuals 
that are infected with HIV-1 and the levels of CXCL13 correlated with levels of CXCL10 in 
advanced disease.73  They showed a 21% decrease in serum levels of CXCL13 after a year of 
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HAART.  In a follow-up study, Regidor et al. reevaluated the effect of highly active 
antiretroviral therapy (HAART) on serum levels of molecules associated with immune activation 
and inflammation.74  It was shown that CXCL13 levels decrease by 40% two to three years after 
HAART initation.  They also established a correlation between baseline CD4 and CXCL13 
levels.  Higher levels of CD4+ T cells resulted in greater decrease of CXCL13 after HAART.  
Similarly, Cagigi et al. (2008) identified altered CXCL13 production by B cells that are 
increasingly responding to CXCL13 in HIV-1 infected patients.75  They also found CXCL13 
protein expression in LNs of HIV-1 infected individuals located within the GC light zone and 
they showed CXCL13 protein expression in a pattern that resembles the follicular DC network.75  
Much of the work on CXCL13 and HIV-1 is based on evaluating a possible role for CXCL13 in 
B-cell abnormalities and dysfunction during HIV-1 infection, which are additional hallmarks of 
HIV-1 infection.  There are significant B cell abnormalities marked by polyclonal activation, 
hypergammaglobulinemia, and circulating immune complexes.13,76  Given that CXCL13 is 
responsible for trafficking of B cells into the marginal zones of follicles, it is possible that 
modifications to its expression might contribute to the B cell dysfunction occurring in HIV-1 
infection.  
1.6 PANETH CELLS AND ANTIMICROBIAL PEPTIDES 
The bacterial load of the small intestine is minimal but increases greatly in the colon.77  
Among the factors that keep the levels of bacteria in the small intestine low, are the antimicrobial 
constituents that are expressed and secreted by Paneth cells.  Paneth cells are specialized 
epithelial cells located in the crypts of Lieberkühn that are present throughout the small intestine 
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(Figure 1 and Figure 2) and these cells increase in number as the concentration of bacteria 
increases to the terminal ileum .77  
 
Figure 1. Schematic diagram of the small intestinal villus-crypt architechture. 
 
Intestinal stem cells reside at the neck of the crypt.  Cells that migrate toward the crypt base 
differentiate into Paneth cells. Inset: Paneth cells release their secretory vesicles into the narrow 
crypt lumen. (Used with permission, from Cellular and Molecular Life Sciences)78 
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Figure 2. Histology of the human small intestinal crypts. 
 
A. Low-power view of paraffin-embedded section of normal adult ileum stained with 
hematoxylin and eosin. Arrows denote Paneth cells at the base of the crypts. (Inset: Higher-
power view of Paneth cells.) Arrow denotes Paneth cell secretory granules. B. Paraffin-
embedded section of adult ileum stained with phloxine-tartrazine. Arrows denote Paneth cells. 
(Used with permission, from Cellular and Molecular Life Sciences)78 
 
Although most of what is secreted by Paneth cells is lysoyme,77,79 defensins are also 
generated and released by these specialized intestinal epithelial cells.  These defensins are 
secreted by and are contained within the secretory granules of Paneth cells.77,80,81  Paneth cells 
also express other antimicrobial agents that aid in host defense.77,81-86  These include secretory 
phospholipase A2 
77
(sPLA2), RegIIIγ, and tumor necrosis factor (TNF)-α.  Antimicrobial peptides 
(AMPs) secreted by Paneth cells have several physiologically overlapping roles in the intestine.   
Those functions include shaping the composition of and limiting the number of commensals 
populating the small intestine, protecting the intestine and its stem cells from invading 
pathogens, and acting as paracrine signaling molecules.77,85  Ayabe et al. have described Paneth 
cells as responsible for the homeostatic environment of the intestinal villi and crypts by 
regulating microbe infiltration.82  Paneth cells express sensors that trigger responses that protect 
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the epithelium of the small intestine.  These sensors include toll-like receptors (TLRs) and 
nucleotide-binding domain leucine-rich repeat containing receptors (NLRs), (e.g., NOD2).  
TLR9 acts by sensing CpG DNA around Paneth cells and stimulating degranulation.87 NOD2 
senses bacterial peptidoglycan muramyl dipeptide (MDP) around Paneth cells.  A deficiency in 
the nod2 gene is associated with decreased α-defensin expression and antimicrobial activity. 88  
These pattern recognition receptors (PRRs) in concert with AMPs assist in preventing 
bacterial translocation by protecting intestinal epithelial cells (IECs), thereby maintaining the gut 
epithelial barrier and intestinal homeostasis.89  IECs and Paneth cells secrete several types of 
AMPs.  As previously mentioned, those include defensins, cathelicidins and other larger AMP 
molecules.  
Defensins are small, cationic, amphipathic peptides.  These proteins contain a disulfide 
bond structure that allows them to protect IECs from invasion by creating pores in the bacterial 
cell membrane.  Similar to chemokines, they contain conserved regions that are rich in cysteine 
residues.  There are three groups of defensins: α, β, and θ-defensins.90,91  α-defensins are 
released by epithelial cells and Paneth cells, as well as, neutrophils and macrophages in humans, 
non-human primates and rodents.77 Humans and non-human primates (NHPs) contain between 
five and six α-defensins (HNP 1-4 and HD-5 & HD-6 in humans; RED1-6 in NHPs) (refs).  HD-
5 and HD-6 are processed into their pro-peptide form by trypsin once they are secreted by Paneth 
cells, where as HNP1-4 are processed by matrix metalloproteinase 7 (MMP-7) just as cryptidins 
are processed in mice.92  β-defensins (hBDs) are secreted by epithelial cells, including 
enterocytes and keratinocytes, in all mammalian species.  hBD1 is the only β-defensin known to 
be contitutively expressed in the gut, whereas hBD2, hBD3, and hBD 4 are stimulated upon 
pathogen recognition.93-95  θ-defensins differ from α- and β-defensins in their structure.77  They 
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have a cyclic configuration and are active in non-human primates.96  In humans, the peptide 
signal sequence of the θ-defensin gene contains a premature stop codon that inhibits the protein 
from being produced.97  Nonetheless, the repaired version (Retrocyclin) is being explored as a 
topical microbicide.98 
In general, defensins have antimicrobial activity at low micromolar concentrations, yet 
Paneth cells produce effective local concentrations than are minimally needed to be 
bactericidal.82,86  In 2004, Tanabe et al. localized the mRNAs of rhesus macaque paneth cell α-
defensins, which they termed rhesus enteric α-defensins (REDs) in the small intestine.  They 
found that these defensins had antibacterial activity against E. coli, L. monocytogenes, S. aureus, 
and Vibrio cholera at concentrations lower than 10µg/ml.   
Antimicrobial peptides have also been shown to possess anti-viral properties.  Several 
studies have investigated the potential for defensins to have anti-HIV capabilities.  Wang et al. 
measured the binding capabilities of α and θ defensins to HIV-1.  They found that retrocyclin-2 
was able to bind to gp120 and CD4 and provided protection from HIV-1 infection in vitro.99 
They also provided evidence that human alpha defensins 1, 2, and 3 also bind to gp120.  More 
recently, retrocyclin RC-101, has been investigated for its potential to provide protection against 
HIV-1 transmission.  Gupta et al. provide evidence that RC-101 prevents X4 and R5 HIV-1 
variant transmission in a cervical tissue-based organ culture model and is a strong candidate for 
development of an HIV-1 entry-inhibiting microbicide.98  Another study investigating the impact 
of α defensins on HIV-1 disease progression found that immature DCs produce alpha defensins 
1, 2, and 3 that could protect against progression of disease.100   
 Another family of AMPs includes the cathelicidins.  Cathelicidin structures include a 
conserved cathelin domain, signal peptide domain and a C-terminal antimicrobial domain that 
18 
varies among different species.  LL-37 is a member of the cathelicidin group of AMPs, and is the 
only cathelicidin found in humans.101  LL-37 is known as human cationic antimicrobial protein 
(hCAP18) in its precursor form.  This peptide is converted to its mature form by cleavage from a 
serine protease.102  LL-37 is expressed by epithelial cells, neutrophils, and macrophages, and can 
exert antibacterial, anti-fungal, and anti-viral activity.103  Its bactericidal activity can be directed 
toward Gram(+) or Gram(-) bacteria.104  LL-37 is another AMP that contains chemokine-like 
function.   It is chemotactic for human peripheral monocytes, neutrophils, and CD4 T 
lymphocytes.82  In chemokine-like fashion, its expression can also be constitutive or induced. 
Stimulation of LL-37 expression is induced by bacterial byproducts such as butyrate,105 vitamin 
D3,99 pro-inflammatory cytokines, or injury. In contrast, bacterial infection by Shigella or 
Neisseria or bacterial exotoxins106 can down-modulate LL-37 expression.106,107  Inhibition of LL-
37 expression has been linked to virulence.108  
  Ganguly et al. 2009, investigated the role LL-37 plays in inflammatory psoriasis.  They 
and Chamilos et al, 2012 showed that this cathelicidin forms complexes with extra-cellular self-
RNA.  By forming these complexes they are able to induce TLR7 and TLR8 activation and 
stimulate the production of IFN-α by pDCs and TNF-α and IL-6 by mDCs.109,110   
Regenerating islet-derived protein 3 gamma (Reg3γ) is an antimicrobial lectin expressed 
by Paneth cells.89  It was revealed in 2006 by Cash et al. to specifically target Gram(+) bacteria 
by binding to their peptidoglycan layer.  Reg3γ belongs to a family of secreted proteins that are 
made up of conserved sequence motifs in C—type lectin carbohydrate domains.  Reg3γ 
expression has been found largely in the small intestine,89 but also in conducting airways.111 
Bacteria112,113 and mucosal damage114 cause inflammatory responses that increase 
gastrointestinal expression of mouse RegIIIγ.115 
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 There are other AMPs that act to eliminate pathogens in the small intestine, differing in 
their mechanism compared to defensins.  Lipocalin 2 (Lcn2) expression is induced by IL-22116 
and IL-17117 during inflammation.  Lcn2 acts to inhibit bacterial growth by binding to iron 
sequestering siderophores.69,118  It acts bacteriostatically by binding to and inactivating 
enterochelin.  It was shown that lcn2 transcription is induced during infection by Salmonella 
typhimurium and is secreted into the intestinal lumen of rhesus macaques.119  Lcn2 secretion is 
also stimulated by TLRs on immune cells that sense bacteria.   
 Much in the way chemokines and AMPs have overlapping functions, Chemerin is a 
protein chemotactic for GPCR-chemokine like receptor 1 (CKLR1),120 and also is suspected of 
displaying antimicrobial properties.   The predicted structure of chemerin contains a conserved 
region of cysteine residues that mimics antibacterial cathelicidins, such as LL-37.   Kulig et al. 
have recently shown how chemerin has antimicrobial activity toward E. coli and K. 
pneumoniae.121     
 Overall, there are several types of AMPs produced as a result of the innate immune 
defenses in the GI tract.  Paneth cells are specialized epithelial cells that express multiple types 
of AMPs, including defensins and lysozyme, in response to microbes in the small intestine.  In 
addition to defensins there are other categories of AMPs.  Cathelicidins and lectins are examples 
of those AMPs.  It has been established that chemokines and AMPs have overlapping 
antimicrobial and chemotactic functions.      
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1.7 THE INTESTINE AS A SITE OF VIROLOGIC AND IMMUNOLOGIC 
ACTIVITY DURING HIV/SIV INFECTION 
The gastrointestinal tract is recognized as a site of dramatic T cell loss and immune 
activation during HIV-1 infection.  The importance of the gut in HIV infection is evident with 
the amount of HIV replication and loss of mucosal CD4+ T cells115,122-125 but intestinal 
enteropathy was first seen in 1984 by Kotler et al.  Intestinal enteropathy includes inflammation 
to the intestinal epithelial layer with villous atrophy, crypt hyperplasia, and villous blunting.126-
128  In 1993, it was reported that rhesus macaques with SIV infection also suffered from severe 
gastrointestinal dysfunction.126,129  They also were found to have chronic inflammation, crypt 
villus blunting, and crypt hyperplasia. 127,129   
Damage to the epithelial barrier in the GI tract has been suspected to allow microbial 
translocation to occur, leading to chronic immune activation during infection.123,130,131  Microbial 
translocation constitutes the passage of pathogens across the mucosal layer of the GI tract.  When 
bacterial endotoxin crosses this barrier, it can travel to the LNs and disseminate systemically 
throughout the body.132  In 2006, Brenchley and Douek reported that microbial translocation is a 
cause of systemic immune activation in chronic HIV-1 infection.133  They used 
lipopolysaccharide (LPS) as an indicator for microbial translocation and compared levels of 
plasma LPS in controllers and progressors to uninfected rhesus macaques.  More recently, Klatt 
et al. showed that there was increased microbial translocation in pigtailed macaques (PTMs), 
which correlated with increased immune activation and associated with increased levels of T 
cells generating IL-17, even in the absense of overt infections.  They suggested that there is a 
relationship between microbial translocation and disease progression in these PTMs.130   
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In 2006, Brenchley and Douek also compared the plasma LPS levels in SIV-infected 
natural hosts, sooty mangabeys, to uninfected sooty mangabeys and found similar low levels of 
immune activation.133  They reasoned that the differences in LPS levels in natural hosts could 
provide a clue into their ability to maintain the epithelial barrier and their inability to develop 
pathogenic infection.   African NHPs such as sooty mangabeys and African green monkeys are 
natural hosts of SIV and have been found to tolerate SIV infections.  The levels of plasma viral 
RNA and the depletion of CD4+ T cells in the gut in non-pathogenic infection are similar to that 
of pathogenic SIV, yet these natural hosts do not progress to AIDS.  There are several factors 
that have been suggested to contribute to this lack of disease progression: 1) natural hosts have 
higher numbers of CD8+ T cells than macaques; 2) there is less CD4+ cell apoptosis; 3) they 
lack T cell activation in blood, peripheral LNs and in the gut; 4) they also possess an anti-
inflammatory immune activation profile whereas pathogenic infection leads to a pro-
inflammatory state of immune activation; and 5) they express lower levels of CCR5 on CD4+ T 
cells in blood, LNs and mucosal tissues  than non-natural SIV hosts.134-137 
Chronic immune activation in pathogenic SIV infection is associated with progression to 
AIDS.138-141  Microbial translocation has been identified as a contributor to immune activation 
induction.   Several factors lead to the translocation of microbes from the lumen into the lamina 
propria including a reduction in the Th17 population.139  Natural hosts of SIV infection serve an 
ideal model to determine SIV pathogenesis because they display many of the characteristics that 
non-natural hosts do, however, they do not progress to AIDS.  
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1.8 SUMMARY 
Chemokines and their receptors have an established role in HIV and SIV infection with 
regards to viral entry into target host cells, yet there are functions these chemoattractant proteins 
possess that have not been fully defined.  The HIV/AIDS epidemic began over three decades ago 
and through extensive research with both small and large animal models, the pieces to this 
complex viral infection are emerging.  Chemokines and their receptors contribute to the 
movement of the very cells that the virus targets, yet it is these very proteins that can be 
engineered to fight the virus.  A major anatomic landmark for HIV-1 infection is in the GI tract, 
a tissue compartment that innately expresses one of the body’s best immune barriers enabling it 
to maintain an almost sterile environment for much of its lengths in the small intestine.  
Understanding how HIV-1 manipulates the chemokine network and how it counteracts such an 
extensive defense system is essential to developing therapeutics and vaccines against the virus.   
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2.0  STUDY PREMISE 
2.1 RATIONALE 
In 1983, the virus that causes AIDS was identified as human immunodeficiency virus 
(HIV-1).10  To date, the complex nature of the host’s response to the virus is still intensely 
studied.  Amongst the contributing factors to the host responses are chemokines.  Studies of 
inflammatory chemokines have focused on their ability to draw cells to sites of inflammation, 
and attention to the role of homeostatic chemokines in HIV-1 infection has been concentrated on 
changes in their constitutive expression.  The chemokines CCL3, CCL4, CCL5 and CXCL12 are 
the corresponding ligands for a small subset of chemokine receptors that permit HIV-1 infection 
of susceptible cells.  CCR5 and CXCR4 are HIV-1 co-receptors that allow infection by 
macrophage and T cell-tropic viruses, respectively.  There is evidence that demonstrates SIV 
infection is associated with modifications to the expression levels of CCR5.17  In addition, 
studies have also shown that the expession levels of CXCL9 and CXCL13 are increased in the 
spleens of AIDS-developing macaques.7  CXCL13 is a constitutively expressed chemokine 
responsible for the migration of lymphocytes into the germinal centers of lymphoid tissues.  
Constitutively expressed homeostatic chemokines have multiple functions in immunity.  
Chemokines exhibit several functions that overlap those of antimicrobial peptides.  In the 
gastrointestinal tract, Paneth cells produce antimicrobial peptides as an innate immune 
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mechanism to protect the epithelium from pathogenic infection.  Clarifying the functions of 
chemokines, and determining the effects HIV-1 infection has on chemokine and antimicrobial 
peptide expression has yet to be fully defined.  The overall hypothesis for these studies is that 
SIV infection leads to changes in the expression of lymphoid chemokine CXCL13 and 
antimicrobial peptides in lymphoid and intestinal tissues. 
2.2 SPECIFIC AIMS 
Specific Aim 1: Measure the effects of SIV infection on the expression of CXCL13 
and other homeostatic chemokines in multiple tissue compartments at different stages of 
infection.  Chemokines play an important role in lymphocyte migration during immune 
responses.  Homeostatic chemokines consitutively expressed during the non-inflammatory state 
but also can be induced during an infection.  During an investigation into the expression levels of 
inflammatory chemokine, CXCL9, during HIV-1 infection, an induction of homeostatic 
chemokine CXCL13 was found in the spleen of AIDS-developing macaques.  I hypothesized that 
during SIV infection there are an induction in the expression of homeostatic chemokine CXCL13 
and its ability to draw responder cell populations.  Histologic staining methods were used to 
visualize and measure patterns of expression and localization of major homeostatic chemokines 
(e.g., CXCL13 and CCL21) and local immune cell populations in multiple cynomolgous 
macaque lymphoid and intestinal tissues across disease stages.  This allowed me to characterize 
the lymphoid and intestinal environments from SIV-infected and AIDS-developing macaques 
and identify changes in CXCL13 expression.   
 
  25 
Specific Aim 2: Determine whether SIV infection induces changes to Paneth cell 
phenotype and Paneth cell chemokine expression in macaque small intestine. Chemokines 
have protective roles in the intestine beyond immune cell recruitment.  These collective functions 
could potentially be important during diseases that cause gastrointestinal inflammation such as 
SIV infection.  After discovering that Paneth cells express CXCL13, I sought to determine 
whether expression levels of factors expressed by Paneth cells were altered during SIV infection.  
I hypothesized that there is a modification to Paneth cell phenotype during SIV infection.  To 
address this, I examined Paneth cell expression profiles of Paneth cell-associated factors, as well 
as, antimicrobial peptides and chemokines in tissues from healthy macaques and compared them 
to tissues from SIV-infected and AIDS developing macaques. Additionally, I examined factors 
such as Trypsin 2 that could potentially be involved in modulating antimicrobial peptide function 
in Paneth cells. 
Specific Aim 3: Characterize the populations of antimicrobial peptides, including 
chemokines, produced by Paneth cells. I hypothesized that the repertoire of antimicrobial 
peptides expressed by Paneth cells is larger than previously described.  It has been demonstrated 
that many chemokines can act as antimicrobial peptides.  I have found in my initial studies that 
CXCL13 and other small intestinal antimicrobial peptides such as α-defensin 6 are expressed in 
the crypts of the small intestinal villi, but not by the large intestine.  It is conceivable that other 
antimicrobial peptides are expressed in previously unidentified compartments in the small and 
large intestine during SIV infection.  To address this, I examined the locations in which AMPs 
are expressed in macaque tissues and determine the effects of SIV infection on their expression 
via immunostaining methodologies and in situ hybridization.   
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Summary:  Altogether, these studies assessed possible modifications to the patterns of 
expression of homeostatic chemokines and AMPs in multiple tissue compartments during SIV 
infection.  They provide new insight into the expression of antimicrobial agents from Paneth 
cells.  As such they have the potential to impact our understanding of mucosal immunology, 
homeostatic chemokine function, and host protective mechanisms against microbial 
translocation. 
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3.0  MATERIALS AND METHODS 
3.1 ANIMALS AND TISSUE PROCESSING 
These studies were performed under the approval and guidance of the University of 
Pittsburgh Institutional Animal Care and Use Committee.  Adult cynomolgous macaques 
(Macaca fascicularis) were used in this study and were inoculated intrarectally with the 
pathogenic SIV/DeltaB670 isolate.142  These animals and their clinico-virologic states have been 
described previously143 and are included here for immediate referral (Table 1).144,145  Fixation 
and processing of tissues at necropsy were completed as described and were placed in storage at 
-80°C for approximately 2-5 years prior to sectioning.146   Frozen tissue sections were cut from 
fixed, cryopreserved tissues at 10µm, thaw-mounted on microscope slides (SuperFrost Plus; 
Fisher), and stored at -80°C until use.  
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Table 1: Study Animals and Clinico-Virologic States. 
Animal Stage of infection Virus* 
Week 
post-infection 
Viral load 
in plasma† 
(copies/ml) 
Clinical 
findings 
      
M5602 Uninfected None NA ND§ Normal 
M6202 Uninfected None NA ND Normal 
M6802 Uninfected None NA ND Normal 
M7102 Uninfected None NA ND Normal 
M13402 Uninfected None NA ND Normal 
M13502 Uninfected None NA ND Normal 
M5702¶ Exposed/ 
uninfected 
SIV/DeltaB670 2 ND Normal 
M7402¶ Exposed/ 
uninfected 
SIV/DeltaB670 2 ND Normal 
M6002 Acute SIV/DeltaB670 2 2,600,000 Normal 
M7902 Acute SIV/DeltaB670 2 3,100,000 Normal 
M8002 Acute SIV/DeltaB670 2 1,450,000 Normal 
M13202 Acute SIV/Delta B670 3 41,300,000 Normal 
M19102 Acute SIV/Delta B670 2 380,000,00 Normal 
M13002 Clinical latency SIV/DeltaB670 8 180 Normal 
M13102 Clinical latency SIV/DeltaB670 8 3,600,000 Normal 
M5802 AIDS SIV/DeltaB670 49 1,950,000 Weight loss, CD4+ 
T-lymphocyte 
decrease 
M5902 AIDS SIV/DeltaB670 14 1,750,000 Weight loss, CD4+ 
T-lymphocyte 
decrease, lymphoma 
M6102 AIDS SIV/DeltaB670 62 1,100,000 Soft stools 
M6302 AIDS SIV/Delta670 42 1 Diarrhea 
M7002 AIDS SIV/DeltaB670 48 640,000 Weight loss, CD4+ 
T-lymphocyte 
decrease, watery 
diarrhea 
M12402 AIDS SIV/DeltaB670 42 4100 Weight loss, CD4+ 
T-lymphocyte 
decrease, PCP 
M12802 AIDS SIV/DeltaB670 37 286,000 Weight loss, CD4+ 
T-lymphocyte 
decrease, PCP 
*Intrarectal infection. 
†Real-time RT-PCR was used to determine plasma viral loads at necropsy. 
§ND, not determined. 
¶SIV was undetectable in plasma 
  29 
3.2 IN SITU HYBRIDIZATION 
In situ hybridization (ISH) for all chemokine (including CXCL13), defensin, and AMP 
mRNAs were performed as described.147  Specifically, the protocol included first post-fixing 
slides in 4% paraformaldehyde (PF) for 20 min, then rinsing them in 70% ethanol for 20 min, 
followed by 5 min in 85% ethanol, and then 5 min in 95% ethanol.  Slides were allowed to dry 
until tissues were completely free of moisture and then pretreated by microwaving in 0.01 M 
citrate buffer (Invitrogen; pH 6.0).  Tissue sections were acetylated in 0.25% acetic anhydride 
and 0.1 M triethanolamine twice for 10 min at room temperature and dehydrated in graded 
ethanols for 5 min each and allowed to completely dry.  Hybridization reactions were completed 
by combining 10% hybridization buffer, 10mM of ATP, CTP, and GTP (In vitro transcription 
kit), and 35S–labeled UTP.  Probes were completed by adding 2M dithiothreitol (DTT) and 
allowed to hybridize overnight at 50°C. Tissue sections were then placed in a series of washes 
and lastly subjected to emulsion autoradiography with varying exposure times depending on the 
target mRNA.  
3.3 IMMUNOHISTOCHEMISTRY 
Immunohistochemistry (IHC) was performed on tissues as previously described (17).  
Briefly, cut tissue sections were post-fixed in 1% PF for 5 min and then washed in graded 
ethanols for 5 min each and allowed to dry completely.  Slides were then pretreated in a heat 
source (Table 2), and in a pretreatment buffer (Table 2) for 10-20 min and allowed to cool for 30 
min.  Slides were then rinsed twice in 1X PBS for 3 min.  Tissues were incubated with an 
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antibody (Table 2) for 1 hour at room temperature in a humid chamber.  A parallel tissue on the 
same slide was incubated with a control antibody, either a concentration matched isotype or Ig 
negative control.  The primary antibodies were then detected with secondary antibody 
SuperPicture Kit (Zymed Laboratories, South San Francisco, CA) according to the 
manufacturer’s instructions.  The kit was matched to the source of the primary antibody, All 
tissues were subsequently counterstained with hematoxylin (Fisher Chemicals, Fairlawn, NJ), 
then placed in graded alcohols for 5 min, xylenes for 5 min and mounted with glass coverslips 
with Permount (Fisher) and allowed to dry overnight.  
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Table 2: Antibodies used in these studies. 
Antibody Supplier Catalog No. Pretreatment 
Buffer 
Heat Source Dilution 
      
CXCL13 R & D 
Systems 
AF801 Dako Target 
Retrieval 
buffer (DTRB) 
Microwave 2 
min Power 2, 8 
min Power 4 
(MW) 
1:50 
CD20 Dako M0755 NaCitrate MW 1:100 
CD79a Fisher MS-357-R7 NaCitrate MW 1 drop 
CD35 Santa Cruz  sc-52644 DTRB Retriever 1:250 
DEFA6 Sigma HPA019462 NaCitrate MW 1:1000 
E-cadherin BD 
Biosciences  
61081 NaCitrate MW 1:1000 
Ki67 Dako M-7240 DTRB Steamer 1:100 
Lysozyme ThermoFisher PA1-29680    
      
 Controls     
IgG Dako  AB108C * ** *** 
Mouse IgG2a Dako X0943 * ** *** 
Mouse IgG1 Dako X0931 * ** *** 
Rabbit Ig Dako X0936 * ** *** 
      
CCL21 
Additional Antibodies Examined  In These Studies# 
R & D 
Systems  
AF366    
CCL28 Santa Cruz sc-27337    
CXCL12 R & D 
Systems 
AF310-NA    
CXCR5 Santa Cruz sc-8179    
Defensin  Abd Serotec MCA1465T    
DEFA5 Abcam AB62757    
E. coli Dako B0357    
Lgr5 Abgent AP2745d    
TLR9 Santa Cruz sc-13215    
NOD2 Santa Cruz sc-71714    
      
* Control antibody pretreatment buffer was matched to target primary antibody pretreatment buffer 
** Control antibody heat source was matched to target primary antibody heat source 
*** Control antibody dilution was calculated and matched to target primary antibody concentration and dilution 
# Multiple pretreatment buffers, heat sources, and antibody dilutions were used in an attempt to optimize a protocol to use these 
antibodies, however, the optimization was unsuccessful. 
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Simultaneous detection of CXCL13 protein and either DEFA6 or BDEF2 mRNA was 
performed by conducting IHC prior to completing the ISH protocol.  Tissues were pretreated by 
microwaving in 1X Dako Target Retrieval buffer (Cat no. S1699, Dako ) for 2 min at power 
setting 2, for 8 min at power setting 4, and then allowed to cool for 30 minutes covered.  Slides 
were rinsed with 1X PBS twice for 3 min, and then blocked with one drop of Dako Protein Block 
(Cat no. X0909 Dako)  for 10 min.  Subsequently, 100ul of goat anti-CXCL13 primary antibody 
(Cat. no. AF801, R&D Systems 1:50) were added to one tissue section on each slide and 100ul 
of goat anti-IgG antibody (Cat. No AB108C Dako) were added to the second tissue section.  
They were incubated in a humid chamber for 1 hr.  Tissues were then rinsed twice in 1X PBS for 
3 min.  They were subsequently incubated with the anti-goat secondary HRP-conjugated 
antibody (Invitrogen; Anti-goat SuperPicture Kit) for 10 min  at room temperature in a humid 
chamber.  Slides were rinsed one last time and allowed to incubate in the humid chamber with 
diaminobenzene (DAB) (Invitrogen; SuperPicture Kit) for 10 min at room temperature.  Slides 
were rinsed then for a few seconds in MilliQ water and then immediately placed in 0.1M 
triethanolamine (pH) with 500ul acetic anyhydride to progress into the acetylation step of the 
ISH protocol.  The remaining ISH steps were followed as described above except that all DTT 
concentrations were reduced to 10 mM. 
 
3.4 IMMUNOFLUORESCENCE STAINING 
Single color immunofluorescence staining of macaque tissues was performed by first 
post-fixing and pretreating slides as mentioned above.  Tissue sections were then incubated in a 
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humid chamber with a protein block (Dako) for 10 min, then an unconjugated primary antibody 
diluted in 1X PBS at room temperature for one hour.  Each antibody was subsequently detected 
with a conjugated secondary antibody (i.e., donkey anti-goat antibody conjugated to Alexa Fluor 
488 or Alexa Fluor 647).   For two-color immunofluorescence staining, CXCL13, and either 
DEFA6 or CD20 were detected by simultaneously incubating goat anti-CXCL13 detected by 
donkey anti-goat Alexa Fluor 647 and rabbit anti-DEFA6 (Sigma, Catalog No. HPA019462, 
1:1000) detected by donkey anti-rabbit antibody conjugated to Alexa Fluor 488 for 1 hour at 
room temperature.  All tissue sections for immunofluorescence were treated with 
Autofluorescence Eliminator (Chemicon International) for 15 minutes before mounting with 
Prolong Gold Antifade with DAPI for nuclear staining (Molecular Probes).   
3.5 REAL-TIME RT-PCR 
Total RNAs were purified from snap-frozen axillary and mesenteric LN, spleen, ileal and 
colon samples from SIV-infected and control cynomolgous macaques.  CXCL13 mRNA 
expression was measured using both a real-time RT-PCR SYBR Green assay (Applied 
Biosciences, Foster City, CA, USA) and a designed set of primers and probe generated by Dr. 
Shulin Qin using Primer Express software.  Primers and probes for DEFA6, TLR9, NOD2, 
Reg3γ, RTD-1, CAMP, DEFA5, ß-GUS, and E-cadherin mRNA targets were commercially 
available (Applied Biosystems, Foster City, CA, USA) (Table 3). The comparative cycle 
threshold (Ct) method was employed to calculate mRNA expression levels relative to an 
uninfected macaque that served as the calibrator, with β-GUS serving as the endogenous control 
(Godfrey et al).   
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Table 3: CXCL13 Real-time RT-PCR primers and probes 
Gene Forward Primer Reverse Primer Probe 
    
CXCL13 CCAGACGCTTCATTGATCGA ATGATTTCTTTCCTTGGACAACCA 6FAM-
TTCAAATCTCGCCTCGTGGG
A 
 
 
 
Table 4. Real-time RT-PCR primers and probes 
Gene Probe Catalog No. 
   
DEFA6 Taqman Rh02913163_m1 
TLR9 Taqman Hs00152973-m1 
NOD2 Taqman Hs002523394_m1 
Reg3g Taqman Hs01595404_m1 
RTD-1 SybrGreen/ 
Taqman 
Rh02790032_m1 
CAMP Taqman Rh02787757_m1 
DEFA5 Taqman Hs00360716_m1 
E-cadherin Taqman Hs01023894_m1 
βGUS Taqman Hs99999908_m1 
 
3.6 CLONING OF PARTIAL CDNAS  
To generate partial cDNAs containing the DEFA6, BDEF2, and RTD-1 open reading 
frames (ORFs), RNA was purified from cryopreserved cynomolgous ileal tissue and cDNA 
synthesis was performed as described (2).  A human Reg3γ cDNA was purchased from Open 
Biosystems (ThermoFisher Scientific, Lafayette, CO).  Primers used for PCR amplification were 
designed based on the corresponding human sequences for α-defensin 5 and β-defensin 2 
(Genbank accession numbers AY859407 and AF040153).  The resultant forward and reverse 
primers are listed in Table 4.  PCR products were ligated into the pGEM-T vector (Promega), 
screened by colony PCR and DNA sequenced. 
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Table 5. Cloning primers 
Gene Forward Primer Reverse Primer 
AMPs   
DEFA6 rhDEFA5_F2_CF_CTCACCATCCTTGCTGCCATTC rhDEFA5_R2_CF_CTAGGAAGCTCGGCGACAGCA 
BDEF2* SS_HBD2_F1_CATCAGCCATGAGGGTCTTG  SS_HBD2_R1: CTCATGGCTTTTTGCAGCATT  
RTD-1* SS_RTD1_F1_GGAGACCCGGGACAGAGGAC SS_RTD1_R1: 5’-AAAGAGAGAAATCTTGCAACAAGGTA 
DEFA1* SS_GTGACCCCAGCCATGAGG SS_CTGGGTTGTCTGTTGGAATCTG 
Lcn2 BFJ.hu.LCN2.F1_ATG CCC CTA GGT CTC CTG TG  BFJ.hu.LCN2.R15'- TCA GCC GTC GAT ACA CTG GT  
Chemerin BFJ.hu.chemerin.F1_ATGCGACGGC TGCTGATCCC                                                                       BFJ.hu.chemerin.R1_TTA GCT GCG GGG CAG GGC CT                                                                                    
Trypsin2 HuTryp2_F_CL_TGC CCC CTT TGA TGA TGA TG HuTryp2_R1_CL_TTA GCT GTT GGC AGC TAT GG 
Reg3γ SQ_hu.Reg3g_F1_ATG CTG CCT CCC ATG GCC CT-3' SQ_hu.Reg3g_R1_CTA GTC CTT GAA CTT GCA GAC ATA 
GGG T 
Chemokines   
CXCL13 TRRHBCA1 F2_AGACAGAATGAAGTTCATCT TRRHBCA-1R2_GTGGAAATATCAGCATCAGGG 
CCL19 TRRHMIP3BF1_ATGGCCCTGCTACTGGCCC TRRHMIP3BR1_TTAACTGCTGCGGCGCTTCATCTT 
CCL21 TRRH6CKF1_ATGGCTCAGTCACTGGCTCTGA TRRH6CKR1_CTATGGCCCTTTAGGGGTCTG 
CCL25 TRRHTECKF_ATGAACCTGTGGCTCCTG TRRHTECKR1_TCACAGTCCTGAATTAGCTGA 
CXCL12 TRRHSDF1AF1_GCCATGAACGCCAAGGTCGTGG TRRHSDF1AR1_TTACTTGTTTAAAGCTTTCTCCAG 
mCXCL13 BFJ.m.CXCL13_F1_5' GAACTCCACCTCCAGGCAGA 3' BFJ.m.CXCL13_R1_5' CTTTTGAGATGATAGTGGCT 3 
   
SIV AGGGCTCAATCTGCCAGCCTCTCCGCAGAG CTCTGCGGAGAGGCTGGCAGATTGAGCCCT 
 GGAACACCCAGGCTCTACCTGCTAGTGCTG CAGCACTAGCAGGTAGAGCCTGGGTGTTCC 
 CACTCTGCCCAGCACCGGCCAAGTGCTGGT ACCAGCACTTGGCCGGTGCTGGGCAGAGTG 
 TGGCAGCTTTATTGAAGAGGTCTTTAAGCA TGCTTAAAGACCTCTTCAATAAAGCTGCCA 
3.7 PHLOXINE-TARTRAZINE STAINING 
Tissues used for visualization of Paneth cell granules were sectioned at 10 µm and then 
mounted on super-frost glass slides.  They were post-fixed in 4% paraformaldehyde for 20 min 
and then dehydrated for 20 minutes in 70% ethanol, and then 5 minutes in 85% and 95% 
ethanols.   These tissues were then stained by a modified protocol of Lendrum’s procedure.  
Specifically, tissues were stained with hematoxylin for 2 minutes, and then washed in MilliQ 
water for 5 minutes.  They were then transferred into the phloxine solution for 20 minutes.  
Tissues were then rinsed in new milliQ water three times with agitation for 30 seconds and then 
blot dried for 5-10 seconds.  Next, the tissues were placed in the tartrazine solution for 5 hours 
and 45 minutes and subsequently rinsed in 95% ethanol twice for 5 minutes.  Last, the tissues 
were placed in xylenes for 5 minutes and then mounted with a glass coverslip with Permount and 
dried overnight at room temperature.  
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3.8 IMAGE CAPTURE AND ANALYSIS 
Images of in situ hybridization, immunohistochemistry and immunofluorecence tissue 
sections were captured on a Nikon (Melville, NY) E600 microscope mounted with a SPOT 
charged-couple device (CCD) (Diagnostic Instruments, Sterling Heights, MD) camera.  The 
MetaVue software package (Universal Imaging, West Chester, PA) was used to view captured 
images.  Confocal microscopy images were captured on an Olympus Fluoview 500 microscope 
in the University of Pittsburgh Center for Biological Imaging with kind assistance from 
microscopy expert Jason Devlin.     
3.9 PHYLOGENETIC ANALYSES 
Human and rhesus (RED) α defensin sequences were first identified and obtained by 
queries submitted on the NCBI BLAST server.  ClustalX (2.0) software (www.clustal.org) was 
used to align all human α-defensin, RED, and other rhesus and cynomolgous macaque  α 
defensin sequences.  They confirmed by a bootstrapped phylogenetic analysis using SEQBOOT 
with 1,000 replicates, followed by DNAdist (with Kimura 2-parameter method), Neighbor-
joining and consense programs from the PHYLIP 3.69 package 
(http://www.evolution.genetics.washington.edu/phylip.htlm).  
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3.10 STATISTICAL ANALYSES 
All statistical analyses were performed with the Prism software package.  Real-time RT-
PCR data were analyzed using the two-sample t test and Mann-Whitney nonparametric test.  A p 
value <0.05 was considered significant.  To quantify correlations between SIV PVLs and fold-
change in AMP mRNA, the Pearson and Spearman-ranked correlation coefficients (rho) were 
determined. P-values of ≤0.05 were considered statistically significant. 
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4.0  RESULTS 
4.1 CXCL13 MRNA AND PROTEIN ARE LOCALIZED TO ADJACENT 
MICROANATOMIC COMPARTMENTS IN MACAQUE LYMPHOD TISSUES 
To understand better CXCL13 expression in lymphoid tissues and to define potential 
changes in CXCL13 expression during pathogenic SIV infection, we examined mRNA 
expression patterns in lymph node (LN) and spleen tissues by ISH.  Cells producing CXCL13 
mRNA localized to a ring around germinal centers (GCs) in LN tissue sections (Figure 3A).  
Subjacent tissue sections were immunostained for CXCL13 protein and, unexpectedly, CXCL13 
protein signal was intensely localized to the center of the GCs (Figure 3A).  In these regions, 
there were networks of CXCL13 clearly visible after immunofluorescent staining for CXCL13 in 
LNs (Figure 3A).  In addition, in LN paracortices there were individual cells that stained for 
CXCL13.  Parallel staining of subjacent tissue sections with control goat Ig did not yield specific 
signal (not shown).  The mRNA and protein expression patterns of CXCL13 in macaque spleen 
tissues were similar to those in LNs (Figure 3B).  These data indicate that CXCL13 producer 
cells are localized in a microanatomic compartment distinct from and immediately adjacent to 
that harboring the highest levels of CXCL13 protein in the centers of GCs.   
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Figure 3. CXCL13 protein and mRNA localize to different microanatomiccompartments in 
lymph node and spleen.  
 
A. Immunohistochemistry (top images), immunofluorescent (top AIDS center-right image) and in situ hybridization 
(bottom images) detection of CXCL13 protein and mRNAs in uninfected, acutely SIV-infected, AIDS-developing 
macaque LN tissues; B. Immunohistochemistry (top images) and in situ hybridization (bottom images) detection of 
CXCL13 protein and mRNAs in uninfected, acutely SIV-infected, AIDS-developing macaque spleen tissues. 
Isotype and sense controls were clear and contained no signals (far right images). (MZ: Mantle zone; GC: Germinal 
center; Original magnification = x200)   
 
CXCL13 expression in LN and spleen tissues was also examined across SIV disease 
states by staining tissues from SIV/DeltaB670 infected animals that have been previously 
examined for inflammatory chemokine expression in lymphoid 145 and lung 144 tissues.  We 
compared expression patterns in LNs from uninfected, acutely SIV-infected, and AIDS-
developing macaques and found that CXCL13 mRNA expression was upregulated during acute 
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infection and maintained at high levels during AIDS (Figure 3A and 3B).  In contrast, CXCL13 
protein expression increased to a limited extent across disease states.  The distribution of 
CXCL13 expression signal appears to expand during SIV infection leading to the presence of 
CXCL13 mRNA beyond the outer zone of the GC into the center and throughout the GC.  This 
could suggest an increase in the number of CXCL13-producing cells recruited to the region, or 
an induction of the amount of CXCL13 produced by cells localized to this microanatomic 
compartment.  Parallel analysis of spleen tissues from the same macaques yielded similar results.  
Altogether these findings suggest that SIV directly or indirectly induces CXCL13 expression 
levels resulting in modification to CXCL13 expression patterns and, therefore, disparate 
localization of mRNA and protein.   
4.2 LOCALIZATION OF CCL19, CCL21, AND CXCL12 AND RESPONDER CELL 
POPULATIONS  IN MACAQUE LYMPHOD TISSUES 
CXCL13 is one of a group of homeostatic chemokines expressed in lymphoid tissues.  
CCL19 and CCL21 are also homeostatic chemokines abundantly expressed in the thymus, LN 
and spleen.  These chemokines induce migration of CCR7+ DCs, B cells, and T cells.  
Previously, our lab found the expression of homeostatic chemokine CCL21 was reduced during 
SIV infection in rhesus macaque LN and spleen tissues.148  In addition, CCL19 expression in 
macaque LNs was found to be low in the absence of infection.148  Here, we sought to determine 
if those same changes to CCL19 and CCL21 occurred in SIV-infected lymphoid tissues of 
cynomolgous macaques.    ISH and IHC for CCL21 in mesenteric LN and spleen tissue sections 
was carried out to examine changes in expression patterns and levels as a function of SIV 
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infection.  We found a dense pattern of CCL21 expression in the paracortex regions of the LNs 
surrounding GCs and lymphatic vessels (Figure 4).  We did not find any changes to CCL21 
expression in the LN of the cynomolgous macaque during SIV infection.  However, as in rhesus 
macaques, there is a decrease in CCL21 expression during acute SIV infection in spleen tissues 
that continues into AIDS (Figure 6).  Unlike CCL21, CCL19 in the spleen increases in acute 
SIV-infected tissues and that increase is maintained during AIDS (Figure 6).  This data was also 
seen in rhesus macaque lymphoid tissues.   
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Figure 4. CCL21 mRNA is localized to the paracortex in cynomolgous macaque mesenteric 
lymph nodes.  
 
In situ hybridization detection of CCL21 mRNA in uninfected, acutely SIV-infected, AIDS-
developing macaque spleen tissues; Sense controls were clear and contained no signals. (PC: 
Paracortex, GC: germinal center, SC: subcapsule; Original magnification = x200)   
 
In addition to identifying changes in homeostatic chemokine expression in lymphoid 
tissues, we attempted to identify cell populations localizing to the same microanatomic 
compartment as CXCL13.  Therefore, we examined markers CD20, CD79a, and CD35 for 
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mature B cells, immature B cells, and follicular dendritic cells (FDCs), respectively all cells that 
can reside in LN GCs (Figure 5) to determine possible CXCL13 producing cells.  Mature B cells 
were found primarily in GCs of uninfected SIV-infected macaques, although there were also 
regions of the paracortex of the LN that contained appreciable markers of individual CD20+ 
cells.  In comparison to mature B cells, immature B cells expessing CD79a localized mostly to 
GCs.   Staining for CD79a had a distinct pattern from CD20 in that there was a darker ring of 
CD79a+ cells around the GCs and a lighter zone of staining in the center of the GC.  CXCL13 
has been described as being generated by stromal cells in lymphoid tissues.53  Therefore, we 
stained for the FDC specific marker, CD35.  CD35 expression in GCs was in a pattern similar to 
both the mRNA and protein expression of CXCL13, with GCs containing a lighter ring of 
expression around the GC, like that of CXCL13 mRNA, and a darker center of CD35 expression, 
like that of CXCL13 protein.  Overall, there was an overlap in the expression pattern of CD20+ 
cells, CD79a+ cells, and CD35+ cells.  Not one cell population completely mimicked the 
expression pattern of CXCL13.  Examining changes in each of these cell markers did not reveal 
striking differences between uninfected and SIV-infected LNs.     
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Figure 5. B cells and follicular dendritic cell expression patterns in cynomolgous mesenteric 
lymph nodes.  
 
Immunohistochemistry, detection of mature B cells (CD20), immature B cells (CD79a), and 
follicular dendritic cells (CD35) in uninfected, acutely SIV-infected, AIDS-developing macaque 
LN tissues; Immunohistochemistry detection of proliferation marker Ki67 in uninfected, acutely 
SIV-infected, AIDS-developing macaque LN tissues. Isotype controls were clear and contained 
no signals. (Original magnification = x100)   
 
 To examine changes in cell proliferation during SIV infection the presence of the marker 
Ki67 was identified (Figure 5).  In uninfected macaques, cell proliferation was mostly within the 
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GC.  Examining nearly subajacent tissue sections for CD20 and CD79a suggests that many of 
these cells are B cells.  In LNs from acute SIV-infected macaques, Ki67 is mostly concentrated 
in GCs, with individual cells that are positive for Ki67 scattered throughout the paracortex.  The 
pattern of cell proliferation in AIDS-developing macaques contrasted significantly from 
uninfected and acutely SIV-infected macaques.  The paracortex and GC regions in LNs of AIDS-
developing macaques had similar numbers of Ki67+ cells where there was an almost even 
distribution of cell proliferation in GCs.  Comparing CXCL13 expression patterns to Ki67+ cell 
expression across disease states suggests in uninfected and acutely SIV-infected macaques could 
contain more proliferating cells that are also localized with CXCL13.  This is not found in AIDS-
developing macaques, where the pattern of Ki67 is no longer highly concentrated in GCs.  
 To identify possible modifications to local cell populations in the spleen during SIV 
infection, and in an attempt to determine colocalization of these cells with CXCL13, CCL19 and 
CCL21, we examined the expression CD20, CD79a, and CD35 to distinguish between mature 
and immature B cells and FDCs on subadjacent tissue sections (Figure 6).  The pattern of CD20+ 
cells is adjacent to but not colocalized with the signal for CCL21 and CCL19 whereas the pattern 
for CD79a positive cells is contained within CCL21 and CCL19 producing cell populations.  The 
expression of CD79a also appears in a similar pattern to CXCL13 protein in the spleen of 
uninfected and acutely SIV-infected tissues.  The pattern of CD79a expression on subadjacent 
tissues sections of AIDS-developing tissues appear to localize with CCL19 and CCL21 mRNA 
expression and suggests colocalization.  In uninfected tissues, CD35 expression was in 
periarteriol lymphoid sheaths (PALS) and contained three distinct zones of expression.  CD35 
expression in acutely SIV-infected and AIDS-developing macaques was similar to the expression 
of both CCL21 and CCL19 (Figure 6).  We observed changes in the expression patterns of 
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CD20+, CD79a+, and CD35+ in the spleen of AIDS-developing tissues.  These findings suggest 
modifications to the presence of these cell populations during SIV infection that could be driven 
by differences in CCL19 and CCL21 expression in adjacent regions of the lymphoid tissues.  
Similar to the LN, there is overlap of the expression patterns between each of these cell 
populations and CXCL13.  
 
Figure 6. Expression patterns of CCL19, CCL21, and responder cells in spleen. 
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In situ detection of CCL19 and CCL21 in uninfected, acutely SIV-infected, and AIDS-
developing macaque spleen tissues. Immunohistochemistry detection of mature B cells (CD20), 
immature B cells (CD79a), and follicular dendritic cells (CD35) in uninfected, acutely SIV-
infected, AIDS-developing macaque spleen tissues. Isotype controls were clear and contained no 
signals. (Original magnification = x200)   
 
HIV-1 utilizes primarily two chemokine receptors for entry into cells.38  Those receptors 
are CCR5 and CXCR4.37,38  CXCL12, another member of the homeostatic chemokine family, is 
the ligand for CXCR4 and is one of the chemokines responsible for the movement of 
lymphocytes during angiogenesis.  To determine if SIV infection altered the expression of this 
homeostatic chemokine, given the importance of its receptor to viral entry, we utilized ISH to 
localize the patterns of cells expressing CXCL12 mRNA (Figure 7).  In the LNs, CXCL12 
expression was largely contained within the medulla and efferent lymphatic system, and in the 
spleen, its expression is throughout the red pulp sinuses.  We found that the levels of CXCL12 in 
the LN and spleen increased during acute SIV infection as compared to uninfected tissues, 
whereas AIDS-developing macaques had CXCL12 expression levels similar to uninfected 
animals.  Our results could suggest that cells expressing CXCR4, the CXCL12 chemokine 
receptor, would be less likely to exit out of lymphoid organs via the efferent lymphatics given 
the reduction in CXCL12 expression.   
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Figure 7. CXCL12 expression increases in the medullary regions of lymph node and spleen 
during SIV infection. 
 
A. In situ hybridization detection CXCL12 mRNA in uninfected, acutely SIV-infected, AIDS-
developing macaque LN (top row) and spleen tissues (bottom row); Sense controls were clear 
and contained no signals. (Original magnification = x200)   
 
With CXCL13 expression upregulated during SIV infection, we sought to determine if 
there were relationships between this CXCL13 expression and SIV RNA expression.  On 
subadjacent tissues, we conducted ISH for SIV mRNA and visually compared GCs for CXCL13 
and SIV expression levels (Figure 8).  There were no apparent associations between changes in 
SIV expression and CXCL13 expression in the lymph nodes or spleen in uninfected animals or 
during acute-SIV infection.  Where CXCL13 formed a dense ring of mRNA around the follicle, 
there was a light cloud of SIV RNA contained in the center of the GC.  However, during AIDS 
there was one notable change.  Those GCs that contained dramatic increases in CXCL13 
expression and had expansion of the GCs also contained what has been described as unspliced 
SIV RNA.  FDCs harbor immune complexes on their surface and contain unspliced viral 
genomic RNA rather than being productively infected by SIV.149  
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Figure 8. Expansion of follicles and CXCL13 expression in the spleen coincides with 
changes in expression patterns of SIV RNA. 
 
  In situ hybridization detection CXCL13 mRNA in AIDS-developing macaque spleen (left 
images) and SIV (right images); Sense controls were clear and contained no signals. (RP: Red 
pulp, WP: White pulp, CA with arrow: Central arteriole. Original magnification = x200)   
   
4.3 CXCL13 IS EXPESSED IN PANETH CELLS 
Intestinal tissues are considered to be one of the largest lymphoid organs and are a site in 
which many CD4+ T lymphocytes are lost during HIV-1 and SIV infection 150.  Additionallly, 
CXCL13 expression has been found in GALT in patients with ulcerative colitis.68  Therefore, we 
  51 
examined the microanatomic distribution of CXCL13 in different regions along the 
gastrointestinal (GI) tract.  Using ISH and IHC, we localized CXCL13 mRNA and protein to 
lymphoid follicles throughout the intestines, including in duodenum, jejunum, ileum, and colon, 
again with mRNA+ producer cells distributed in a three dimensional spherical shell surrounding 
high levels of CXCL13 protein within GCs (Figure 9 and figure 10). 
 
Figure 9. CXCL13 mRNA expression in GALT and Paneth cells in the macaque intestine.   
 
In situ hybridization detection of CXCL13 mRNAs in uninfected, acutely SIV-infected, and 
AIDS-developing macaque duodenum (left images), jejunum (left center images), ileum (right 
center images), and colon (right images) tissues.  (PC: Paneth cell, F: Follicle. Arrow denotes 
PC. Original magnification = x200)   
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Figure 10. CXCL13 protein expression in the GALT and Paneth cells in the macaque 
intestine.  
 
Immunohistochemistry detection of CXCL13 protein in uninfected, acutely SIV-infected, and 
AIDS-developing macaque duodenum (left images), jejunum (left center images), ileum (right 
center images), and colon  (right images) tissues.  (PC: Paneth cell, F: Follicle. Arrow denotes 
PC. Original magnification = x100 and x200)   
 
Interestingly, we observed intense expression of CXCL13 mRNA and protein in a subset of cells 
in the crypts of Lieberkühn (Figure 9, Figure 10, and Figure 11).  Cells expressing CXCL13 in 
crypts were observed in duodenal, jejunal, and ileal tissues from all 16 macaques studied, but 
were not observed in colon.     
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Figure 11. CXCL13 expression in Paneth cells of the small intestine. 
 
Immunohistochemistry detection of CXCL13 protein (left images) and in situ hybridization 
detection of CXCL13 mRNAs (right images) in uninfected, acutely SIV-infected, and AIDS-
developing macaque tissues. Sense controls were clear and contained no signals. (Original 
magnification = x100)   
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 In the crypts of Lieberkuhn, Paneth cells are specialized intestinal epithelial cells that 
produce AMPs and are found only in the small intestine 151.  The regional distribution of 
CXCL13 expression in intestinal crypts we observed could be due to its production by Paneth 
cells.  To determine if Paneth cells were the source of CXCL13 in the intestinal crypts, we 
individually and simultaneously stained for α-defensin 6 (DEFA6), which is an AMP uniquely 
expressed by Paneth cells.152,153  In macaque small intestine, we found Paneth cell secretory 
granules, DEFA6 protein, and DEFA6 mRNA localized to intestinal crypts in patterns identical 
to those obtained for CXCL13 (Figures 12A-12B, and Figures 14A-B), and similar to CXCL13, 
DEFA6 was expressed in the jejunum and ileum, but not in the colon.  Simultaneous IHC for 
CXCL13 protein and ISH for DEFA6 mRNA (Figure 12C) demonstrated their co-localization to 
the same cells in crypts.  In addition, two-color immunofluorescence staining and confocal 
microscopy confirmed that CXCL13 and DEFA6 are co-expressed by Paneth cells in 
intracellular granules, with most CXCL13 signal overlapping a large proportion of the DEFA6 
signal (Figure 12H).  These findings confirm that that source of CXCL13 in intestinal crypts is 
the Paneth cell and are to our knowledge the first to show the expression of a lymphoid 
homeostatic chemokine by this specialized intestinal epithelial cell.   
To verify if other AMPs were expressed by the same intracellular granules in Paneth cells 
we simultaneously conducted IHC for CXCL13 protein and ISH for DEFA1, BDEFA2, RTD-1, 
and Reg3γ (Figure 12C-G).  Expression of mRNAs for each of these AMPs colocalized with 
CXCL13 in some granular regions, however, both signals did not always overlap.  This could 
suggest that Paneth cellss vary in their ability to produce specific AMPs.   
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Figure 12. Antimicrobial peptides α-defensin 6, α-defensin 1, β-defensin 2, rhesus θ-
defensin 1, and Reg3g colocalize with CXCL13 expression in the ileum. 
 
A. Phloxine-tartrazine staining for Paneth cell granules in the crypts of the Leiberkuhn of the 
macaque ileum. B. Immunohistochemical detection of cynomolgous DEFA6 protein in macaque 
ileum tissues (Original magnification = x200). C. Double label immunohistochemical detection 
of CXCL13 protein and in situ hybridization for alpha defensin-6 mRNAs in macaque ileum 
tissues. D. Double label for CXCL13 protein and DEFA1 mRNAs in the ileum. E. Double label 
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for CXCL13 protein and BDEF2 mRNAs in the ileum; F. Double label for CXCL13 and RTD-1 
mRNAs in the ileum.. G. Double label for CXCL13 protein and Reg3γ mRNAs in the ileum; H. 
Immunofluorescent detection of DEFA6 and CXCL13 protein colocalization in macaque ileum 
tissues. Isotype and sense controls (inset of D.) were clear and contained no signals. (Original 
magnification = x400; Black silver grains represent mRNA signal; Brown staining represents 
protein signal) 
4.4 CXCL13 IS UNIQUELY EXPRESSED IN PANETH CELL AMONGST A SUBSET 
OF CC AND CXC CHEMOKINES 
To determine whether other chemokines also were expressed strongly in intestinal crypts, 
or whether CXCL13 was unique in this property, we examined the localization of mRNA 
producer cells of multiple chemokines along the macaque GI tract.  These included CCL25, a 
ligand for CCR9 that directs the trafficking of intestinal homing T and B lymphocytes (Figure 
14), as well as CXCL1, CXCL9, CXCL10, CXCL11, CXCL12, CCL19, CCL20, and CCL21 
(Figure 13).  Yang et al. evaluated a group of chemokines for their antimicrobial potential and 
found that approximately 50% of the chemokines they evaluated exhibited antimicrobial 
activity.154  Based on their data, we chose to determine if Paneth cells also expressed a subgroup 
of those chemokines that demonstrated some of the greatest antimicrobial activity.  We did not 
find any of these other chemokines, which have been shown to exhibit antimicrobial activity,154 
expressed by Paneth cells making expression of CXCL13 unique.   
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Figure 13. Unique expression of CXCL13 in Paneth cells in the small intestine.  
 
 
 
In situ hybridization CXCL13 (far left image), CXCL1, CXCL9, CXCL10, CXCL11 (top row 
images), CXC12, CCL19, CCL20, and CCL21 (bottom row images) mRNA in uninfected 
macaque ileum tissues.  Sense controls (not shown) were clear and contained no signals. 
(Original magnification = x200) 
 
CCL25 is known to be expressed by small intestinal epithelium, and consistent with this, 
the mRNA expression patterns for CCL25 differed greatly from CXCL13, with CCL25 producer 
cells found uniformly across the epithelium of the small intestine and not in the GALT, Paneth 
cell laden crypts, or colon.  None of the other chemokine producer cells were localized to 
intestinal crypts, and therefore not in Paneth cells (Figure 14D-F).   
  58 
 
Figure 14. Antimicrobial peptides α-defensin 6 and CCL25 mRNA are present in the 
cynomolgous macaque small intestine.  
 
In situ hybridization of DEFA6 (A-C) and CCL25 (D-F) mRNA in uninfected, acutely SIV-
infected, and AIDS-developing macaque jejunum, ileum, and colon tissues.)  Sense controls (not 
shown) were clear and contained no signals. (Original magnification = 100X)  
 
To determine if cells known to express CXCR5 and with the potential to respond to 
CXCL13 were also localized near Paneth cells, we identified CD20+ mature B cells by IHC and 
immunofluorescence (IF) (Figure 15).  Our results show that most CD20+ cells are localized to 
follicular regions (Figure 15A and C).  There are also regions with small numbers of individual 
CD20+ cells (Figure 15B).  It is possible that this signal could be consistent with drawing B cells 
to crypts.  However, by performing two-color immunofluorescent staining for CXCL13 and 
CD20 in the intestine, we found CD20+ cells were not localized immediately adjacent to 
CXCL13 producing Paneth cells.  CXCL13 (displayed in green) appears to be secreted into the 
lumen and contained within the granules of Paneth cells, whereas the CD20+ (displayed in red) 
B cells are located in the lamina propria (Figure 15E).  CXCL13 and CD20 does appear to 
colocalize in follicular regions and we see overlapping green and red signals (Figure 15F).  
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These results provide evidence that support our hypothesis that CXCL13 produced by Paneth 
cells is functioning as an AMP and not particularly to direct migration of B cells that may 
contain its receptor CXCR5.  T cells also express the CXCL13 receptor CXCR5 and it is 
possible those cells could be responding to CXCL13 in this microenvironment if it were 
functioning as a lymphoid chemokine, however, the presence of T cells was not examined in 
these studies.   
 
Figure 15. CXCL13 and mature B cells do not colocalize in Paneth cells in the ileum.   
 
A-C. Immunohistochemistry detection of CD20 in the macaque ileum E-F. immunofluorescent 
detection of CXCL13 and CD20 protein in macaque ileum Paneth cells and ileum follicle. 
Isotype controls (not shown) were clear and contained no signals. (Original magnification = 
x200)    
 
To determine if expression of CXCL13 in Paneth cells was unique to cynomolgous 
macaques, we explored avenues to detect its expression in other species of animals.  We utilized 
IHC and ISH to look for CXCL13 mRNA expression in multiple compartments of uninfected 
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rhesus macaque and murine intestinal tissues.  In the rhesus macaque, CXCL13 expression also 
was found in both lymphoid follicles and in Paneth cells (Figure 16).   
 
Figure 16. CXCL13 protein expression in the rhesus macaque small intestine.   
 
Immunohistochemistry detection of CXCL13 protein in the rhesus macque ileum. Isotype 
controls (not shown) were clear and contained no signals. (Original magnification = x100; PC 
and arrows denote Paneth cells in crypts)    
 
In mouse intestinal tissues, however, CXCL13 expression was only observed in GALT and not 
Paneth cells (Figure 17).  These findings indicate there are differences in gut immunity and host 
defenses across species.  Several factors, including disparities in the gut microbiome could drive 
the selective expression of a homeostatic chemokine in Paneth cells of NHPs but not in other 
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small animal species, although examination of a larger number of species will need to be 
performed.   
 
Figure 17. CXCL13 mRNA is not present in Paneth cells in the murine small intestine. 
 
In situ hybridization detection of CXCL13 mRNAs in uninfected mouse A. ileum epithileal and 
B. ileum lymphoid tissues. Sense controls (not shown) were clear and contained no signals. 
(Original magnification = x200)    
4.5 PANETH CELLS CONTAIN A LARGER REPERTOIRE OF ANTIMICROBIAL 
PEPTIDES THAN PREVIOUSLY DESCRIBED 
Paneth cells produce AMPs in the crypts of Lieberkuhn to protect the intestinal 
epithelium and local stems cells from infection.  There are several classifications of AMPs that 
have been described, including defensins, cathelicidins, and lectins.  Given the clear expression 
of CXCL13 by Paneth cells, strongly suggesting it has antimicrobial functions in the intestine, 
we next examined whether other AMPs not previously recognized as expressed by Paneth cells 
are also produced them.  We chose to evaluate a member of several types of AMPs, including a 
β-defensin (BDEF2), a θ-defensin (RTD-1), a cathelicidin (LL-37), a lectin (Reg3γ), as well as 
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other factors that are not typically thought of as an antimicrobial peptides, yet have antimicrobial 
properties.  These would include Lcn2 and chemerin.  Although both DEFA5 and DEFA6 are 
AMPs produced by Paneth cells, β-defensins have not been localized to these specialized cells.  
Unexpectedly, β-defensin 2 (BDEF2) mRNA producing cells were localized to intestinal crypts 
(Figure 18A) and simultaneous ISH for BDEF2 mRNA and IHC for CXCL13 protein revealed 
co-localization to the same cells in crypts (Figure 12E).  Additionally, we found rhesus θ-
defensin 1 (RTD-1) expressed specifically in intestinal crypts, similar to DEFA5 and BDEF2 
(Figure 18B).  In contrast to what was previously known about BDEF2 and RTD-1, macaques 
are known to express Reg3γ as an AMP 89,155, and it is expressed by Paneth cells in response to 
Gram-positive bacteria 89,155.  By using ISH we found Reg3γ was indeed expressed in crypts 
throughout the small intestine but was absent from the colon (Figure 18C).  In summary, these 
findings provide the first evidence that in macaques BDEF2 and RTD-1 are expressed by Paneth 
cells, and expand our understanding of the repertoire of AMPs used by these cells to protect the 
crypts and shape the intestinal milieu. 
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Figure 18. β-defensin 2, θ-defensin 1, and Reg3g are localized to Paneth cells in the 
cynomolgous macaque ileum.  
 
In situ hybridization detection of A. BDEF2, B. RTD-1 and C. Reg3γ mRNAs in cynomolgous 
uninfected macaque ileal tissues. D-F. Sense controls contained no signal. (Original 
magnification = 100X) 
 
In our efforts to identify AMPs, expressed by Paneth cells, we used ISH to examine 
expression of DEFA1 in the small and large intestine.  We found DEFA1 expression by cells in 
the crypts of the small intestine (Figure 19).  We believe this suggests Paneth cells produce 
DEFA1.  DEFA5 and DEFA6 are the only known α-defensins expressed by Paneth cells and our 
findings provide evidence that the repertoire of AMPs produced by Paneth cells is much larger 
than previously described.   
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Figure 19. Cynomolgous macaque α-defensin 1 is localized to Paneth cells in the ileum.  
 
In situ hybridization detection of DEFA1 mRNAs in cynomolgous uninfected (left image), acute 
SIV-infected (center image), and AIDS developing (right image) macaque ileal tissues. Sense 
controls contained no signal (not shown) (Original magnification = 100X) 
 
The presence of some REDs in the small intestine has been established (Tanabe 2004).  
Our laboratory cloned and sequenced confirmed cynomolgous macaque DEFA6 and DEFA1.  
To confirm whether the cynomolgous macaque DEFA6 and DEFA1 sequences we used as 
probes in our studies were the same or distinct from the previously published macaque RED 
sequences, we used phylogenetic analyses to compare the published RED and human α-defensin 
sequences to our cynomolgous macaque α-defensin sequences (ORFs only).  Based on these 
analyses, DEFA6, used here, sequence aligns and phylogenetically groups with the RED6 
sequence previously published by Tanabe et al. (Figure 20).  Interestingly, our DEFA1 
cynomolgous/rhesus sequence was not identical to any of the previously published RED 
sequences.  It did, however, align and closely cluster with the human α defensins 1 and 3 (Figure 
19). This finding suggests that we were able to identify a novel alpha defensin not previously 
identified in cynomolgous macaque Paneth cells.  These findings again suggest that Paneth cells 
express a larger repertoire of AMPs than previously predicted and another α-defensin, other than 
DEFA5 and DEFA6, is expressed by Paneth cells in the cynomolgous macaque.  
  65 
 
Figure 20. Phylogenetic relationships among human, rhesus macaque, and cynomolgous 
macaque defensins.  
 
RED, human, rhesus, and cynomolgous α-defensin sequence clusters are shown. Bootstrap 
values are shown at the corresponding nodes.  
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Chemerin and Lcn2 are not traditionally described as AMPs but they do possess 
antimicrobial properties that could aid in host defense mechanisms.  In our studies we found 
AMPs not previously seen expressed by Paneth cells, therefore, we assessed additional targets 
including chemerin and Lcn2.  Chemerin is similar in structure to cathelicidins and has activity 
against E. coli and K. pneumoniae.  By ISH we determined whether Paneth cells express these 
peptides and determined if there were changes to mRNA expression levels in uninfected, acutely 
SIV-infected, and AIDS-developing macaque ileal and colon tissues.  ISH did not reveal Paneth 
cells as a producer cell type for chemerin.  There were low levels of intestinal epithelial 
expression of chemerin in the ileum and colon, although those levels did not appear to change as 
a function of SIV infection (Figure 21).  Lcn2 binds to siderophores and prevents iron 
sequestration by bacteria, affording it a more direct antimicrobial role compared to chemerin.  
We also evaluated changes to Lcn2 expression in the ileum and colon of SIV-infected tissues by 
ISH and compared them to uninfected tissues.  Based on the mRNA expression pattern in ileum 
Lnc2 is expressed by epithelial cells in the crypts, but its distribution is more widespread 
indicating that expression is not limited to Paneth cells (Figure 21).  
  67 
 
 
Figure 21. Expression patterns of chemerin and Lcn2 mRNAs in the cynomolgous macaque 
ileum and colon.  
 
In situ hybridization detection of A. chemerin and  B. Lcn2 mRNAs in cynomolgous uninfected, 
acute SIV-infected, and AIDS developing macaque ileal (top images) and colon (bottom images) 
tissues. Sense controls contained no signal (not shown) (Original magnification = 100X) 
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4.6 AMTIMICROBIAL PEPTIDE EXPRESSION DURING SIV INFECTION 
 To determine whether SIV infection impacted levels of expression of Paneth cell AMPs, 
including CXCL13, we examined tissues from animals in different stages of SIV infection.  
Admittedly these intestinal tissues were fixed and cryopreserved without attention at the time to 
tissue orientation and interest in Paneth cells, so we were not able to reliably obtain a uniform 
representation of crypts and Paneth cells for quantitative analysis of tissue sections.  However, at 
a qualitative level, there were no obvious differences in the intensities or distributions of signals 
for CXCL13, DEFA6 and BDEF2 of the ISH or IHC data in intestinal crypts.  Uninfected 
animals showed robust expression of CXCL13, DEFA6, BDEF2, RTD-1, and Reg3γ mRNAs.   
ISH data for DEFA1, RTD-1 and Reg3γ show moderate changes to the levels of signal 
intensities across disease states (Figure 17 and Figure 22).  RTD-1 is decreased in tissues of 
acutely-infected SIV macaques as compared to uninfected and AIDS-developing macaques.  In 
contrast, DEFA1 and Reg3γ appears to increase to a small extent during acute-infection increases 
further during AIDS (Figure 19 and Figure 22).   
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Figure 22. θ-defensin 1 and Reg3g mRNAs are localized to Paneth cells in the cynomolgous 
macaque ileum. 
 
In situ hybridization detection of RTD-1 (left images) and Reg3γ (right images) mRNAs in 
cynomolgous uninfected, acute SIV-infected, and AIDS developing macaque ileal tissues. Sense 
controls contained no signal (not shown) (Original magnification = 100X) 
 
Multiple attempts to use a commercially available real-time RT-PCR assay for macaque 
cxcl13 mRNA, and to develop an assay in-house, failed to meet our quality control expectations, 
(meaning that the shapes of the amplification plots were different between different animals).  
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Therefore, accurate measurement of cxcl13 mRNA levels in lymphoid and intestinal tissue RNA 
preparations was not achieved.  Measurements of cxcl13 mRNA levels in RNA preparations 
from homogenized intestinal tissues additionally were complicated by the inability to distinguish 
the contributions of signals from lymphoid follicles versus from Paneth cells.  In contrast, the 
real-time RT-PCR assay for DEFA6 was robust and DEFA6 was expressed uniquely by Paneth 
cells.  Using this assay we found that the levels of expression for this AMP increased 
approximately 10-fold during acute infection and AIDS in the ileum (Figure 23A).  This increase 
in defensin expression is consistent with a recent report that SIV infection leads to induction of 
rhesus enteric defensin (RED).150  In support of this, correlation analyses show a positive 
correlation between SIV viral loads and DEFA6 mRNA ( r2 = 0.53, p value = 0.04) (Figure 23B). 
 
Figure 23. Ileal induction of DEFA6 mRNA during SIV infection is correlated with SIV 
plasma viral loads.   
 
A. DEFA6 mRNA levels were measured in the indicated tissue by using real-time RT-PCR.  B. 
Correlation analyses of DEFA6 mRNA and plasma SIV viral loads (*) denotes statistical 
significance (p-value <0.05) relative to uninfected animals (Mann-Whitney non-parametric test).  
Significant positive correlation was determined by Spearman’s non-parametric correlation 
analyses. Individual animal’s expression values were normalized to a β-GUS endogenous control 
and then normalized to an uninfected control “calibrator” sample. 
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Using real-time RT-PCR, Lcn2 mRNA levels were also measured and revealed that there were 
no significant differences in the expression after SIV infection, although the highest expression 
was observed in a subset of SIV-infected macaques (Figure 24).   
 
Figure 24. Measurement of Lcn2 mRNA expression in cynomolgous macaque ileum tissues.   
 
Lcn2 mRNA levels were measured in the indicated tissue by using real-time RT-PCR.  The mean 
fold-changes in expression relative to an uninfected calibrator sample are shown.  All p-values 
were > 0.05 by Mann-Whitney non-parametric analyses. Individual animal’s expression values 
were normalized to a β-GUS endogenous control and then normalized to an uninfected control 
“calibrator” sample. 
 
LL-37 is a well-known human cathelicidin that has a defined antimicrobial function.156,157  
It has broad antibacterial activity against both Gram (+) and Gram (–) bacteria.  We determined 
whether Paneth cells express this specific AMP and whether there were changes to its expression 
levels after SIV infection in SIV-infected animals compared to those that were uninfected.  
Based on real-time RT-PCR analysis of ileum, there were no significant differences in acute 
SIV-infected or AIDS-developing macaques compared to their uninfected counterparts (Figure 
25).    
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Figure 25. Measurement of LL-37 mRNA expression in cynomolgous macaque ileum 
tissues.  
 
LL-37 mRNA levels were measured in the indicated tissue by using real-time RT-PCR.  The 
mean fold-changes in expression relative to an uninfected calibrator sample are shown.  All p-
values were > 0.05 by Mann-Whitney non-parametric analyses. Individual animal’s expression 
values were normalized to a β-GUS endogenous control and then normalized to an uninfected 
control “calibrator” sample. 
 
4.7 PANETH CELL MARKERS AND SIV INFECTION 
Paneth cells aid in host defense and immunity by protecting the gastrointestinal tract from 
bacterial pathogens.  Upon stimulation by potentially invading bacteria, they secrete AMPs into 
the crypt.  After discovering CXCL13 expression in macaque Paneth cells, we asked whether 
Paneth cell phenotype was affected by SIV infection.  To address this, we evaluated changes in 
protein and/or mRNA expression of multiple commonly known antimicrobial factors generated 
  73 
by Paneth cells.  We also determined whether SIV infection had effects on these factors by 
evaluating their expression levels across disease states.  To accomplish this we measured 
expression levels of Tryp2, NOD2, TLR9, IL-17, and RORγt.   
In mice, matrilysin processes AMPs produced by Paneth cells.158  In humans this function 
belongs to trypsin 2 (Tryp2).158  It has not been determined whether macaques also express 
Tryp2 in Paneth cells, thus attributing this protease the likely function of processing AMPs in 
macaques.  ISH was used to determine if macaques also express Tryp2 in the small intestine.  
Tryp2 was not only expressed in the ileum of the small intestine, but it was also expressed by 
Paneth cells (Figure 26).  This finding suggests that Tryp2 processes AMPs in macaques 
similarly to humans.   
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Figure 26. Trypsin 2 is expressed in Paneth cells in the cynomolgous macaque ileum. 
 
In situ hybridization detection of Tryp2 mRNAs in cynomolgous uninfected, acute SIV-infected, 
and AIDS developing macaque ileal tissues. Sense controls contained no signal (not shown) 
(Original magnification = 100X) 
 
TLR9 acts as a sensor to CPG DNA and in the small intestine stimulation of this TLR 
causes degranulation of Paneth cells.87  To determine if macaque Paneth cells express TLR9 and 
whether there are modification to TLR9 expression in Paneth cells after SIV infection, we 
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attempted to use IHC and real-time RT-PCR to measure possible changes to TLR9 protein or 
mRNA expression.  Immunostaining for TLR9 proved unsuccessful in our tissues, however, in 
homogenized small intestinal tissue RNA preparations, real-time RT-PCR revealed that there 
was a significant decrease in TLR9 expression in AIDS-developing macaques compared to 
uninfected animals (Figure 27), suggesting that SIV infection might influence Paneth cell 
phenotype.  Chronic immune activation in pathogenic SIV infection has been associated with 
microbial translocation.140  A reduction in TLR9 during AIDS could indicate a possible 
contribution to the intestinal enteropathy and microbial translocation that occurs during infection. 
 
Figure 27. TLR9 mRNA expression in significantly reduced during SIV infection in 
cynomolgous macaque ileum tissues.  
 
TLR9 mRNA levels were measured in the indicated tissue by using real-time RT-PCR.  The 
mean fold-changes in expression relative to an uninfected calibrator sample are shown.  (*) 
denotes statistical significance (p-value <0.05) relative to uninfected animals (Mann-Whitney 
non-parametric test).  Individual animal’s expression values were normalized to a β-GUS 
endogenous control and then normalized to an uninfected control “calibrator” sample. 
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Paneth cells likely detect pathogens via multiple PRRs, one of those being NOD2.  
NOD2 senses bacterial peptidoglycan MDP, LPS, and modifications to the nod2 gene are 
associated with chronic inflammatory disease of the small intestine.159,160  Given the chronic 
inflammation in the gut during SIV infection, we sought to determine whether there were 
changes in the expression levels of NOD2 in SIV-infected macaques compared to uninfected 
animals.   Attempts to determine differences in expression of NOD2 by immunohistochemical 
analyses were unsuccessful and real-time RT-PCR showed no differences between uninfected, 
acute SIV-infected or AIDS developing macaques (Figure 28).   
 
Figure 28. Measurement of NOD2 mRNA expression in cynomolgous macaque ileum 
tissues.  
 
NOD2 mRNA levels were measured in the indicated tissue by using real-time RT-PCR.  The 
mean fold-changes in expression relative to an uninfected calibrator sample are shown.  All p-
values were > 0.05 by Mann-Whitney non-parametric analyses.  Individual animal’s expression 
values were normalized to a β-GUS endogenous control and then normalized to an uninfected 
control “calibrator” sample. 
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We also examined changed in cell proliferation of the gut by using IHC and staining for 
Ki67 positive cells in the small and large intestine of uninfected, acute SIV-infected, and AIDS-
developing macaques (Figure 29).  Our results showed no significant changes in cell 
proliferation across disease states or across regions of the gut. 
 
Figure 29. Cell proliferation in the cynomolgous macaque small intestine.   
 
Immunohistochemistry detection of KI67 protein in the macaque jejunum (top row), ileum 
(center row), and colon (bottom row) in uninfected (left column), acutely SIV-infected (center 
column), and AIDS-developing tissues (right column). Isotype controls (not shown) were clear 
and contained no signals. (Original magnification = x100)    
 
 
 
To examine the potential for microbial translocation in our study animals, we attempted 
to identify E. coli in the colon of uninfected, acute SIV-infected and AIDS-developing macaques 
(data not shown).  Due to issues with assay optimization we could not determine whether there 
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were changes in the levels of E. coli across disease states, however, we did not find any E. coli in 
any of our tissues that appeared to have translocated from the lumen into the lamina propria.   
E-cadherin is a cell-to-cell adhesion glycoprotein present in the small intestine and colon 
encoded by the Cdh1 gene.  In mice, knocking out this gene results in changes in Paneth cell 
phenotype.  Maturation of Paneth cells is inhibited, AMP production is reduced, and clearance of 
pathogenic bacteria from the lumen is prevented in Chd1-/- mice.161  Therefore as a measure of 
intestinal epithelial integrity, we sought to determine changes in macaque e-cadherin expression 
(Figure 30).  IHC analyses of this protein in macaque intestinal tissues showed staining of E-
cadherin along the epithelium down into the crypts of the ileum, however it did not show any 
discernible changes in SIV-infected ileum compared to uninfected controls.  
 
Figure 30. E-cadherin protein expression in the cynomolgous macaque small intestine.   
 
Immunohistochemistry detection of e-cadherin protein in the cynomolgous macaque ileum 
uninfected, acutely SIV-infected, and AIDS-developing tissues. Isotype controls (not shown) 
were clear and contained no signals. (Original magnification = x100)    
 
In an investigation of the contributions of IL-17 to the systemic inflammatory response 
syndrome caused by tumor necrosis factor (TNF), it was discovered, in mice, that Paneth cells 
produce IL-17.162  This established a possible new role for IL-17 during an acute inflammatory 
response, beyond production by Th17/Tc17 cells, by showing TNF stimulation results in the 
release of IL-17 by Paneth cells.  Therefore, we explored whether SIV infection alters IL-17 
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mRNA levels in the small intestine.  Real-time RT-PCR did not show any significant differences 
in SIV-infected intestinal tissues compared to uninfected controls (Figure 31).  However, both 
the acutely SIV-infected and AIDS-developing macaque groups contained animals that had 
mRNA expression with a 4-fold increase than any of the uninfected animals.  Given that IL-17 
secretion is also regulated by the presence of T helper 17 cells (Th17) we simultaneously 
examined whether there were any changes to the Th17 population by measuring RORgt mRNA 
levels.  Again, we found no significant changes to RORgt levels in the ileum of SIV-infected 
animals (Figure 32). 
 
 
Figure 31. Measurement of IL-17 mRNA expression in cynomolgous macaque ileum 
tissues.   
 
IL-17 mRNA levels were measured in the indicated tissue by using real-time RT-PCR.  The 
mean fold-changes in expression relative to an uninfected calibrator sample are shown.  All p-
values were > 0.05 by Mann-Whitney non-parametric test.  Individual animal’s expression 
values were normalized to a β-GUS endogenous control and then normalized to an uninfected 
control “calibrator” sample. 
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Figure 32. Measurement of RORgt mRNA expression in cynomolgous macaque ileum 
tissues.  
 
RORgt mRNA levels were measured in the indicated tissue by using real-time RT-PCR.  The 
mean fold-changes in expression relative to an uninfected calibrator sample are shown.  All p-
values were > 0.05 by Mann-Whitney non-parametric test.  Individual animal’s expression 
values were normalized to a β-GUS endogenous control and then normalized to an uninfected 
control “calibrator” sample. 
 
 
 Finally, we evaluated possible relationships between SIV viral loads and AMPs (Table 
6).  Using parametric and non-parametric correlation analyses measurements we determined 
several significant associations.  Our results show a significant Pearson’s correlation between IL-
17 and DEFA6, Lcn2, and NOD2.  We also found significant levels of NOD2 with detectable 
higher levels of Lcn2, LL-37, and TLR9.  There were also positive correlations between levels of 
Lcn2 and LL-37.  By measuring correlations via Spearman rank correficient test, we found a 
positive correlation between SIV PVL and DEFA6 (Figure 23), as well as between TLR9 and 
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LL-37 and NOD2.  IL-17 was once again found correlated with Lcn2 and NOD2.  Lastly, we 
found NOD2 positively correlated with levels of Lcn2.    
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Table 6. Correlation analyses of the relationships amongst SIV and antimicrobial peptides. 
 SIV log10 DEFA6 TLR9 IL-17 RORgt LL-37 Lcn2  NOD2 
SIV 
log10 
 0.47 -0.25 0.20 0.04 0.22 0.33 0.28 
DEFA6 0.53#  -0.17 0.64* -0.33 0.12 0.47 0.18 
TLR9 -0.29 -0.19  0.27 0.00 0.43 0.22 0.70* 
IL-17 -0.18 0.32 0.41  -0.28 0.45 0.91* 0.59* 
RORgt 0.01 -0.38 -0.21 -0.13  0.02 -0.36 -0.20 
LL-37 0.01 0.12 0.60# 0.31 -0.13  0.52* 0.68* 
Lcn2  0.16 0.42 0.19 0.68# -0.48 0.32  0.65* 
NOD2 0.25 0.21 0.67# 0.51# -0.32 0.31 0.51#  
 
*Denotes p-value <0.05 by Pearson’s correlation analyses (green cells). 
#Denotes p-value <0.05 by Spearman’s non-parametric correlation analyses (blue cells).
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4.8 SUMMARY 
Studies from our laboratory previously determined that there was an induction in the 
expression levels of homeostatic chemokine CXCL13 in the spleen of AIDS-developing rhesus 
macaques.  To explore further the expression levels of CXCL13 during SIV infection, we 
evaluated differences in acutely SIV-infected and AID-developing cynomolgous macaque 
CXCL13 expression levels and patterns compared to uninfected macaques.  We found increased 
CXCL13 mRNA and protein levels in both acutely-SIV infected and AIDS-developing 
macaques compared to uninfected macaques.  In addition, we found differences in the expression 
patterns of CXCL13 mRNA and protein.  In our efforts to determine CXCL13 expression levels 
in the GALT, we unexpectedly found CXCL13 expression in Paneth cells in the crypts of 
Lieberkuhn.  We confirmed this finding by demonstrating that DEFA6, a known and uniquely 
expressed Paneth cell AMP, colocalizes within the granules of Paneth cells with CXCL13.  
Additionally, we determined that Paneth cells express a larger repertoire of AMPs than 
previously described.  Our results show that DEFA1, BDEF2, RTD-1, Reg3γ, and Lcn2 also 
localize to macaque Paneth cells in the small intestine, as well as Tryp2, a human AMP 
processing peptide.  The effects of SIV infection on AMP expression were seen in the 
differences in expression levels of DEFA6, RTD-1, and Reg3γ.  Both DEFA6 and Reg3γ had 
increases in mRNA expression during acute SIV-infection that continued in AIDS-developing 
macaques.  RTD-1 mRNA expression decreased in acutely SIV-infected macaques and then 
returned to expression levels similar to uninfected macaques in AIDS-developing macaques.  
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Discovering CXCL13 expression by Paneth cells led us to investigate the effects of SIV-
infection on other Paneth cell-associated factors.  We found a significant decrease in the 
expression levels of TLR9 in AIDS-developing macaques compared to uninfected animals.        
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5.0  OVERALL DISCUSSION 
CXCL13 is a homeostatic chemokine that controls, in large part, the migration of B cells, 
follicular helper T (Tfh 51) cells and DCs into the follicles of secondary lymphoid tissues.   
Because CXCL13 is responsible for trafficking of B cells and Tfh
163
 cells into the marginal zone of 
follicles, it is possible that modifications to its expression might contribute to the B cell 
dysfunction occurring in HIV-1 infection.   Here we have examined the expression levels and 
patterns of CXCL13 in lymphoid tissues, including intestine, and found not only increased 
expression of CXCL13 during infection, but also that SIV infection drives a more disordered 
distribution of CXCL13 producer cells in LN and spleen and that CXCL13 is expressed by 
Paneth cells in small intestine.   
A limited number of studies have examined CXCL13 in the context of HIV-1 or SIV 
infection.  CXCL13 levels are elevated in plasma during HIV-1 infection and correlate with 
levels of CXCL10 in advanced disease.73  In addition, CXCL13 production by B cells is 
increased in HIV-1 infected patients and there is increased migration toward CXCL13 by 
peripheral blood B from patients with advanced disease compared to uninfected controls.75  
CXCL13 protein expression during HIV-1 follicular hyperplasia is associated with the GC light 
zone and the follicular DC (FDC) network.  These reports are consistent with our findings of an 
expansion and redistribution of CXCL13 producer cells in LN and spleen.  In GC immunology, 
CXCL13 drives the migration of B cells and Tfh cells together in the GCs for the generation of 
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high-affinity antibodies.  GCs are also a reservoir for FDC populations that can harbor immune 
complexes.    Therefore, changes in CXCL13 could drive further the movement of these 
populations together, provide the necessary opportunity for FDCs to capture virus on their 
surface, and contribute to the B cell dysfunction that occurs during SIV infection. 
 
There is disparate localization of CXCL13 mRNA and protein in lymphoid tissues  
During pathogenic SIV infection, we had previously identified CXCL13 as one of the 
two chemokines with the largest increases in mRNA expression in spleen tissues.148  We initiated 
the studies here with the goal of obtaining an improved understanding of the immunobiology of 
this chemokine in the macaque model for HIV/AIDS.  We found CXCL13 protein was centrally 
located within GCs whereas CXCL13 mRNA was generally localized in cells defining a shell in 
the mantle and marginal zones of follicles.  This disparate microanatomic localization of 
CXCL13 mRNA and protein was unexpected and underscores the complexity of the in vivo 
immunobiology of chemokines within tissues.  The mechanism by which CXCL13 is 
concentrated within GCs, compared to the spherical shell of producer cells and the more distant 
paracortices is not clear.  There are multiple possible mechanisms, however.  For example, the 
intense staining in the center of the sphere circumscribed by the CXCL13 producer cells could be 
a consequence of bidirectional diffusion away from the producer cells in both the central 
follicular and paracortical directions, resulting in increased overall concentration within GCs and 
a reduced concentration in paracortices.  Alternatively, CXCL13 release might be polarized and 
limited to the follicular surfaces of producer cells.  This would lead to lower concentrations of 
CXCL13 outside the GCs and increased concentrations within the GCs.  In addition, there might 
be an active transport mechanism that maintains the extracellular CXCL13 within the GC, 
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perhaps piggybacking on cells migrating toward the GC or in microchannels.  The latter would 
be consistent with the thin, cord-like structures we have observed (e.g., Figure 1) in LNs and 
spleen.  Furthermore, there might be differential expression of proteases that process CXCL13 in 
lymphoid tissue microcompartments, with a higher concentration of proteases in the surrounding 
paracortices relative to the inside of the GCs.  Such compartmentalization of proteases would be 
consistent with the ability of GCs to harbor immune complexes on FDC surfaces for long periods 
of time 164-166.  Regardless of the mechanism(s), the compartmentalization of CXCL13 within 
lymphoid tissue GCs is consistent with its role in bringing Tfh
Cagigi et al. demonstrated the expression of CXCL13 by immature CD1a+ DCs.
 cells, B cells, and DCs together.   
75  They 
did not, however, find a large amount of CXCL13 expression by mature DCs and suggested that 
this is result of a loss of CXCL13 upon DC maturation.  In an attempt to identify and distinguish 
CXCL13 producer cells from responding cells we evaluated expression of B cells and FDCs by 
immunostaining for CD20, CD79a, and CD35.  Identifying a true pattern of producer cells versus 
responder cells proved difficult by IHC alone because each of their signals contains regions that 
overlapped amongst one another.  The patterns of expression of these cell populations were 
similar to CXCL13, although, not just one population completely colocalized with CXCL13 
mRNA or protein signals.  It is possible that there could be overlapping populations of producer 
and responding cells.  In addition, there were no clear differences in expression levels of these 
cell populations by IHC as a function of SIV infection.  Another cell type that also displays a 
pattern of expression in GCs similar to CXCL13 mRNA but was not evaluated in this study is 
the metallophillic macrophage cell.167  This specialized subset of macrophages has been shown 
to be involved in Ag-trapping in the spleen.167  They have a distinct pattern of expression in the 
outer marginal zone of GCs that is comparable to the pattern of CXCL13.167   
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CXCL13 expression levels are modified during SIV infection 
In this study, we found there were disease-specific changes in CXCL13 expression, with 
the mRNA+ producer cells expanding more broadly into the GCs and surrounding 
microcompartment as the course of infection progressed.  Recently, increases in LN Tfh
168
 cells in 
HIV-1 infected individuals were observed despite the overall reduction in the number of CD4+ T 
cells that occurs during infection .  Given that Tfh cells express CXCR5, the CXCL13 
receptor, as well as CXCL13 per se, the more distributed pattern of CXCL13 producer cells we 
observed could be driven by recruitment and/or expansion of Tfh cells.  In addition, a recent 
comparison between uninfected and SIV-infected rhesus macaque Tfh cells revealed a 5-fold 
induction of CXCL13 expression in Tfh 169 cells that were SIV-infected .  B cell affinity 
maturation and isotype switching occurs in GCs 170, and given the known B cell dysfunction that 
occurs during HIV-1 and SIV infection 163,171-173, it is conceivable that a chemokine that 
orchestrates the migration of these cells into follicles could contribute to humoral immune 
response abnormalities that arise during infection.  Consistent with this notion, it has been argued 
recently that there is a decrease in memory B cell levels due to the distortion of the B cell 
population toward GC B cells and plasma cells during chronic HIV-1 infection 168.  
Alternatively, it was demonstrated that B cells in serum and tissues of HIV-1 infected 
individual’s expressed significantly higher levels of CXCL13, further alluding to a contribution 
by the chemokine to B cell dysfunction.   
Previous studies by our laboratory also have shown modifications to other homeostatic 
chemokine expression levels in rhesus macaques during SIV infection.  In an attempt to examine 
these changes in the cynomolgous macaque model we evaluated mRNA expression patterns and 
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levels by ISH in uninfected, acutely SIV-infected, and AIDS-developing macaques.  Our 
findings show changes to the levels of CCL19 and CCL21 mRNA in the LN and spleen, 
consistent with our previous findings in rhesus macaques.148  CCL19 and CCL21 guide 
lymphocytes and DCs to and within lymphoid tissues via their receptor CCR7 and have 
demonstrated an ability to promote inflammation.174   
CXCL12 is a homeostatic chemokine whose receptor CXCR4 is known for its role as an 
HIV-1 co-receptor.  Mutations in the cxcl12 gene are associated with resistance to HIV-1 
transmission.175,176  To study the expression patterns of CXCL12 between uninfected and SIV-
infected macaques, we examined expression patterns of CXCL12 mRNA in LN and spleen by 
ISH.  There is a visible induction of CXCL12 mRNA expression in the medulla of LNs and 
medullary sinuses of the spleen during acute SIV infection.  HIV-1 strains utilize CXCR4 as an 
entry coreceptor occurs late in infection.  This suggests the selection of CCR5 as an entry 
coreceptor is caused by an inhibition in the shift in tropism.  Gonzalez et al. provided evidence of 
DC-mediated enhancement in the propagation of X4 viruses that was inhibited by the production 
of CXCL12 by mature monocyte-derived DCs (mMDDCs).177  They suggest that DCs present in 
the LNs produce CXCL12 preventing the appearance of X4-tropic viruses.  The induction of 
CXCL12 in our studies could support this finding.   
 
CXCL13 is expressed by Paneth cells in the macaque small intestine 
It has been demonstrated that subsets of chemokines and AMPs possess both chemotactic 
and antimicrobial activity.   A major finding from these studies was the discovery that CXCL13 
is expressed by Paneth cells.  Paneth cells are specialized intestinal epithelial cells that express 
AMPs and proinflammatory cytokines that contribute to innate immunity 151.  The AMPs 
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secreted by Paneth cells have several overlapping roles in the intestine 77, including shaping the 
composition of and limiting the number of commensals populating the small intestine, protecting 
the intestine and its stem cells from invading pathogens, and acting as paracrine signaling 
molecules.77  It has been argued that Paneth cells are responsible for the homeostatic 
environments surrounding the intestinal villi and crypts by regulating microbe infiltration 82.  
Given the expression of CXCL13 by Paneth cells, one of its major functions in the small 
intestine is likely as an AMP, which would not have been anticipated for a LN homeostatic 
chemokine.  The same regional distribution of CXCL13 along the GI tract as other Paneth cell 
expressed AMPs, and the co-localization of CXCL13 and DEFA6 in Paneth cells supports the 
interpretation that CXCL13 functions in vivo as an AMP.  To confirm further that the expression 
of CXCL13 in Paneth cells is likely due to its ability to function as an AMP and not for its 
normal chemotactic function, we sought to determine whether mature B cells, which are known 
to express the CXCL13 receptor CXCR5, were located in the lumen adjacent to Paneth cells 
expressing CXCL13.  Therefore, we evaluated CD20+ mature B cells in the same tissues and did 
not find colocalization of CXCL13 and CD20 in Paneth cells.  CD20 and CXCL13 localization 
in the GALT showed a simlar pattern to the MLNs and spleen supporting the claim that CXCL13 
is providing its known function in this region of the intestine.  However, its lack of colocalization 
with CD20 in Paneth cells suggests that it functions as an AMP in this compartment.  
Furthermore, approximately 50% of chemokines have been shown to possess antimicrobial 
activity in in vitro assays, including CXCL13.154  Amongst the microbes against which CXCL13 
exhibited antimicrobial activity were the intestinal bacteria E. coli and S. aureus.154  This 
antimicrobial activity is consistent with our discovery that CXCL13 is expressed by Paneth cells.  
To explore further the antimicrobial property of CXCL13, we attempted to have a macaque 
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CXCL13 peptide synthesized to use in antimicrobial assays with known gut Gram (+) and Gram 
(-) bacteria.  Our lab previously had success with the synthesis of macaque chemokines 
CXCL11, truncated CXCL11, and CCL20 for use in chemokine inhibition and antimicrobial 
studies, however, the development of the CXCL13 peptide proved to be a challenge.     
To determine if CXCL13 expression in Paneth cells was specific to cynomolgous 
macaques, we examined the expression of CXCL13 in both the rhesus macaque and in the 
mouse, and found differences among the species of animals.  CXCL13 was found in the GALT, 
but is not present in Paneth cells of the mouse, unlike both rhesus and cynomolgous macaques, 
where CXCL13 is present in both GALT and Paneth cells.   
 
The cxcl13 promoter is stimulated by the short chain fatty acid sodium butyrate 
Short chained fatty acids such as sodium butyrate are produced by intestinal bacteria and 
we found that the macaque CXCL13p was induced by this product of bacterial fermentation. 178  
The antimicrobial cathelicidin LL-37 is also stimulated by sodium butyrate 157,179-181.  The 
upregulation of the CXCL13p by microbial products is consistent with our interpretation that has 
CXCL13 has AMP function in the intestine.   
 
The AMP repertoire expressed by Paneth cells is larger than previously described 
In addition to CXCL13, we show here that DEFA1, BDEF2, RTD-1, and Reg3γ are also 
expressed by macaque Paneth cells.  DEFA1 is contained within the granules of neutrophils and 
contributes to human systemic innate immunity.  It has not, however, been shown to be 
expressed by human or macaque Paneth cells.  Lower levels of this AMP, along with DEFA2 
and DEFA 3, were found in patients with inflammatory bowel disease meaning there could be 
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modification to the expression levels of these AMPs during HIV-1 infection, which also causes 
inflammation and intestinal enteropathy.127,128  DEFA1 has been shown by a few mechanisms to 
inhibit HIV-1 infection, including preventing binding of Env to CD4 and co-receptors.  β-
defensins are expressed by epithelial cells in multiple mucosal tissues, including skin, stomach, 
and colon.182  However, they have not been reported to be expressed by Paneth cells.  In addition 
to AMP activity, at least some β-defensins also possess chemotactic activity.  For example, 
BDEF2 is chemotactic for CCR6+ cells,183 cells that are responsive to the chemokine CCL20.  
The θ-defensins are cyclic defensins originally isolated from leukocytes and bone marrow of 
rhesus macaques 184.  Rhesus θ-defensins and repaired human retrocyclin have broad 
antimicrobial properties with inhibitory effects on HIV-1, influenza virus, and a broad swath of 
bacteria.  As with BDEF2, predominant expression in the GI tract by Paneth cells has not been 
reported.  Finally, Reg3γ is an AMP expressed by murine Paneth cells 89 and our findings reveal 
the same for macaque Reg3γ.  Altogether, these findings increase our understanding of the 
composition of the AMP repertoire produced by Paneth cells, the diversity of which likely 
reflects the diverse set of microbes targeted as an innate protective mechanism against microbial 
translocation in the intestinal crypts.   
Finding a significant induction of DEFA6 during SIV infection led us toward examining 
expression levels of other AMPs found to be expressed by macaque Paneth cells during SIV 
infection.  We attempted to utilize ISH and real-time RT-PCR to determine expression level 
differences among uninfected, acute SIV-infected, and AIDS-developing ileal tissues.  
Macroscopic changes to mRNA levels were visualized by ISH for RTD-1 and Reg3γ during 
acute SIV and AIDS disease states.  Fluctuations to the mRNA levels of these AMPs could 
contribute to the subverted gut microbiome during SIV infection.  Attenuated expression of 
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defensins could suggest a compromise to host immunity or may signal the host is attempting to 
prevent a shift toward a state of inflammation.   
 
Paneth cell-associated factors during SIV infection 
Revealing CXCL13 expression by Paneth cells stimulated us to more broadly investigate 
the effects of SIV infection on Paneth cell phenotype.  It has been demonstrated that microbial 
translocation is associated with chronic immune activation in SIV infection and it is conceivable 
that Paneth cells, given their secretion of AMPs in response to invading bacteria, could play an 
important role in this process.  We examined differences in expression of several Paneth cell 
markers to determine if they were altered during SIV infection.  Our findings show most of the 
Paneth cell markers we evaluated were unchanged.  Two exceptions were TLR9 and DEFA6.  
Expression of TLR9 was significantly decreased in AIDS-developing tissues compared to 
uninfected animals.  TLR9 is responsible for recognition of DNA rich in CpG motifs and 
decreases in its expression could signify a weakness in the immune defenses that are beneficial 
for the development of chronic immune activation.  A significant increase in DEFA6, in contrast, 
was found in those same AIDS-developing macaques.  This could provide evidence in an attempt 
by the natural immune processes of the gut to combat any increases in bacterial concentration 
due to a reduction in TLR9.   
Translocation of microbial products into the intestinal lumen stimulates TLRs and 
triggers the immune system into a state of inflammation, activating memory and effector CD4+ 
and CD8+ T cells.  Funderburg et al. investigated T cell activation of peripherial blood 
mononuclear cells (PBMCs) from uninfected individuals by TLR ligands185 and in vitro 
stimulation by microbial TLR ligands induced activation of lymphocyte homing and activation.  
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In our analyses of changes to TLR9 expression during SIV infection, however, we did not find 
significant increases in a Paneth cell- associated TLR9 expression.  This could be evidence 
further to support an avenue for increase immune activation.  One study suggests an inhibition of 
TLR9-mediated recognition of bacterial and viral infection may contribute to chronic activation 
of the immune system.  Their results show how interaction between HIV-1 and SIV gp120 with 
pDCs renders them incapable to responding to TLR9-stimulating pathogens.186  
There is a preferential loss of IL-17 producing CD4+ T cells during the course of SIV 
infection in the gastrointestinal tract.139  Our examination of changes to IL-17 mRNA levels in 
the ileum revealed no significant differences between SIV-infected and uninfected macaques.  
Additionally, there was no decrease in the levels of RORγt in these same animals.  This suggests 
that there was no reduction in the Th17 population during infection in our group of study 
animals.  It is possible there could be differing levels of Th17 cells in other regions of the small 
intestine other than the ileum and there could be a preferential loss of these cells in other 
compartments during SIV infection especially in the colon where damage to the mucosal barrier 
is observed.  Additionally, in our studies we utilized cynomolgous macaques for our animal 
model, where as other studies evaluating the role of IL-17 in microbial translocation was in a 
Pigtail macaque (PTM) animal model.  Klatt et al. showed differences in microbial translocation 
in PTM versus rhesus macaques (RM).  In their PTM, they found significant more gut epithelial 
damage and microbial translocation in PTMs than in RMs.141     
During microbial translocation, there is substantial structural damage to the 
gastrointestinal epithelium in PTMs.141  The epithelial tight junction protein, claudin, has been 
evaluated for its association with microbial translocation.  E-cadherin is a cell-cell adhesion 
protein that that is also involved in maintaining tissue architecture.  A loss in e-cadherin has been 
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shown to attentute Paneth cell maturation.  For our studies, we evaluated alterations to e-cadherin 
expression during SIV infection and found no changes in its expression in acute SIV-infected or 
AIDS-developing macaques compared to uninfected macaques.    
Trypsin is responsible for processing AMPs in the gastrointestinal tract of humans.  In the 
mouse, this activity is conducted by MMP-7.  Results from our studies show that Tryp2 is also 
expressed by macaque Paneth cells.  The use of trypsin in macaques to proteolytically process 
AMPs is reasonable given their close phylogenetic relationship to humans.   
Lastly, we evaluated the relationships between SIV PVL and AMPs by conducting 
correlation analyses.  Where we previously found no significant differences in mRNA levels 
during SIV infection, we now found significant associations between levels of several AMPs and 
Paneth cell-associated factors.  Interestingly, the single correlation with SIV PVL was with 
DEFA6.   
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6.0  SUMMARY 
The importance of evaluating changes to chemokine and chemokines receptor expression 
levels during SIV infection has been demonstrated in studies of not only CCR5 and HIV-1 
coreceptor usage, but also in studies of chemokines such as CXCL9 and CXCL13.7,148   
In normal germinal center biology, T-cell dependent stimulation of antigen occurs and 
activates B cells to migrate into GCs.187  The GCs are divided into distinct zones where cells 
undergo proliferation, clonal expansion and affinity maturation.187  FDCs also reside in these 
regions and have the potential to harbor immune complexes and secrete TNF cytokines.  Tfh also 
migrate into GCs and assist in this development process.  Cyster et al. describe how the 
microarchitecture of the GC is influenced by the distribution and interaction of each of these cell 
types.188  B cells have been shown to be highly motile between each of the zones in the GC.189  
CXCL13 plays a vital role in the movement of each of these cell types throughout each 
microcompartment of the GC given their expression of its receptor, CXCR5.  A hallmark of 
HIV-1 infection is disruption to humoral immunity.163  Hyperactivation and exhaustion of B 
cells, production of short-lived plasmablasts and an increase in the production of B-cell 
stimulatory cytokines190 are all characteristics of B cell dyfunction during HIV-1 infection.  A 
reduction of the levels of these cytokines is seen after the initiation of HAART.74  Similarly, 
there is a reduction in the serum levels of CXCL13.74  Studies evaluating the effects of HAART 
on biomarkers of B-cell activation, found higher baseline levels of CD4+ T cells were associated 
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with greater decreases in CXCL13 levels after HAART.74  Our findings provide further evidence 
to support a possible role for CXCL13 in the disruption of B cell maturation and antibody 
production in GCs during SIV infection.  We found a significant increase if the distribution of 
CXCL13 in follicular regions that coincides with disease progression.  Increases in the 
production of CXCL13 can stimulate the movement of responder cell populations in the GCs and 
have detrimental effects to the B cell maturation process, therefore, having a downstream affect 
on the production of high-affinity antibodies.    
In a compilation of all changes to chemokines, AMP, and Paneth cell-associated factor 
expression into one graphic image (Figure 33), we determined that amongst the chemokines we 
evaluated, CXCL13 exhibits the greatest increase during SIV infection.  Evaluating each group 
separately, we see that there are more fluctuations in the expression of chemokines and AMPs 
than of the Paneth cell-associated factors across disease states.   During HIV-1 infection there is 
a dramatic decrease in the population of T cells located in the GI tract, making it an important 
site of investigation.  In our efforts to elucidate changes in CXCL13 expression in the GALT, we 
made a unique finding.  We observed CXCL13 expression by Paneth cells in the macaque small 
intestine.  For the first time, we provide evidence to support its possible function as an 
antimicrobial peptide by demonstrating colocalization with known Paneth cell marker, DEFA6.  
Therefore, the findings presented here sustain the notion that chemokines function as AMPs.  
This has been demonstrated for many chemokines in vitro, but localization of CXCL13 to Paneth 
cells, which are specialized for production of AMPs, and transcriptional induction of the 
CXCL13p by the intestinal bacterial product sodium butyrate, provides strong support that at 
least a subset of chemokines provide antimicrobial function in vivo.  That a lymphoid 
homeostatic chemokine is functioning in these dual capacities is intriguing and it will be 
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interesting to unravel the possible selective pressures that have led to the multi-functionality of 
CXCL13 and subsets of chemokines generally.  
 
Figure 33. Graphical representation of changes to chemokines and antimicrobial peptide 
expression levels as a function of SIV infection. 
 
Blue cells represent lymphoid chemokines evaluated in the LN and spleen.  Green cells represent 
AMPs evaluated in the intestine.  Varying size cells represent either an increase or decrease the 
level of expression.    
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6.1 FUTURE WORK 
Over the course of this study, our findings led to the development of many questions that 
were not addressed due to time constraints.  The following are areas of study that warrant further 
investigation.   
The most commonly known function of CXCL13 is to drive the flow of lymphocytes into 
the GCs.  Given the B-cell dysfunction that occurs during HIV-1 infection, it would be beneficial 
to conduct CXCL13 inhibition studies to determine the effects on B cell maturation and the 
development of high-affinity antibodies during infection.   
Revealing CXCL13 expression by PCs in the small intestine has lead to many other 
questions regarding this known homeostatic chemokine’s function.  Should this chemokine 
function as an antimicrobial peptide, we are curious about the factors that regulate its expression 
and release from Paneth cells?  Additionally, antimicrobial studies are necessary to determine 
pathogens targeted by CXCL13.  An ex vivo study utilizing intestinal tissue explants could be 
optimized to stimulate Paneth cells.  A measurement of the amount released AMPs and detection 
of CXCL13 can be carried out.  
6.2 PUBLIC HEALTH IMPACT AND SIGNIFICANCE 
The 30th anniversary since the emergence of the AIDS epidemic recently passed and there 
has yet to be a vaccine developed to prevent the further spread of the HIV-1 virus.  A hallmark of 
infection is B cell dysfunction and an inability for the host to develop high-affinity antibodies.  
The production of these antibodies occurs in GCs of lymphoid tissues.  CXCL13 is a 
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constitutively expressed chemokine whose function is to drive the migration of lymphocytes into 
GCs.  Modifications to the expression levels of this chemokines during SIV infection provide 
evidence that warrant further investigation of this homeostatic chemokines and its role in the 
interruption of B cell maturation and antibody production.   
A unique finding in this study was the expression of CXCL13 by macaque Paneth cells.   
In conjunction, we also show other AMPs expressed by macaque Paneth cells that had not 
previously been described.  These results provide the basis for further inquiry into their role in 
maintaining the microbiome of the gastrointestinal tract.   
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